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Context: Despite the availability and accessibility of current diagnostic tools, diabetes 
remains largely under-diagnosed. Biological limitations, discordant assays and conflicting 
diagnostic thresholds together impede the accurate and successful diagnosis of diabetes, 
providing impetus into research for a novel diagnostic tool. 
Aim: Since flux through the five minor glycolytic pathways is increased during 
hyperglycemia, we hypothesized that the genes encoding the regulatory enzymes of such 
pathways may be differentially expressed between control, pre-diabetic and diabetic 
individuals setting the scene for an exploratory diagnostic avenue employing genetic 
biomarkers. 
Experimental procedures: Participants (n=60; n=20 Mixed Ancestry, n=40 Caucasian) were 
recruited from Stellenbosch and Paarl (Western Cape, South Africa) and classified as control, 
pre-diabetic or diabetic. RNA was purified from leukocytes isolated from blood samples and 
OGT, OGA, GFPT1, GFPT2, TKT, TKTL1 and AKR1B1 expression determined by 
quantitative real-time PCR. 
Results: Expression of OGA, OGT, GFPT2 and TKTL1 decreased in pre-diabetic and 
diabetic individuals; while GFPT1, TKT and AKR1B1 expression levels remained largely 
unaffected between the study groups. GFPT2 exhibited ethnic-dependent regulation. 
Conclusion: Differential expression of genes regulating non-oxidative glucose-utilizing 
pathways may offer diagnostic utility in the future and warrant further investigation. 
 





Konteks: Teen spyte van die beskikbaarheid en toeganklikheid van huidige diagnostiese 
instrumente, word diabetes nogsteeds min gediagnoseer. Altesaam belemmer biologiese 
beperkings, teenstrydige toetse en botsende diagnostiese grense die akkurate en suksesvolle 
diagnose van diabetes, wat bydra tot die druifkrag in navorsing vir ‘n nuwe diagnostiese 
instrument. 
Doelstelling: Aangesien die vloei deur die 5 mineur glikolitiese pad weë toeneem gedurende 
hiperglukemie, veronderstel ons dat die gene wat regulatoriese ensieme kodeer in hierdie pad 
weë mag dalk differensieel uitgedruk word tussen kontrol, voor- en, diabetiese individue wat 
die toneel skep vir ‘n ondersoekende diagnotiese laan wat gebruik maak van genetiese 
merkers. 
Materiale en metodes: Deelnemers (n=60; n=20 Gemengde afkoms; n=40 Blankes) was uit 
Stellenbos en die Paarl gewerf (Wes-Kaap, Suid-Afrika) en geklassifiseer as ‘n kontrol, voor- 
of diabeties. RNS was uit witbloodselle gesuiwer wat eers uit bloed monsters geisoleer was 
en OGT, OGA, GFPT1, GFPT2, TKT, TKTL1 en AKR1B1 uitdrukking was bepaal deur 
kwantitatiewe RT-PKR. 
Resultate: Uitdrukking van OGA, OGT, GFPT2 en TKTL1  het afgeneem in voor- en 
diabetiese individue; terwyl GFPT1, TKT en AKR1B1 utidrukkings vlakke meestal 
onaangeraak was tussen die studie groepe. GFPT2 het etiese-afhanglike regulasie vertoon. 
Gevolgtrekkings: Differensiele uitdrukking van gene wat glukose gebruik in nie- 
oksidatiewe pad weë reguleer bied diagnotiese gebruikbaarheid in die toekoms en bevel 
verdere ondersoek. 
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1. LITERATURE REVIEW 
The rapid increase in the incidence and prevalence of type 2 diabetes and its associated 
complications is fast becoming one of the most pressing health concerns of developed and 
developing countries (1). For example, diabetes is responsible for ~4.6 million deaths 
annually and this figure is predicted to increase by more than 50% over the next decade (2), 
(1). Additionally, diabetes healthcare expenditure totalled a considerable ~$465 billion in 
2011, making it not only a global health affliction, but also a worldwide economic burden (2). 
Since the burden of diabetes is progressively shifting towards younger working class 
individuals, the associated economic repercussions are predicted to result in marked increases 
in expenditure (3). Moreover, non-communicable diseases such as cardiovascular diseases 
(CVD) and diabetes account for ~2/3 of all deaths worldwide (4). As a result the United 
Nations General Assembly proclaimed diabetes and other, non-communicable diseases a 
global epidemic in 2011 (5). Thus it is imperative that actions be taken in order to decrease 
the burden that diabetes places on society, our current healthcare structures, as well as its 
debilitating effect on the economy. 
 
1.1 A GROWING GLOBAL EPIDEMIC 
During 2000 the World Health Organization (WHO) revealed that there were ~171 million 
people suffering from diabetes globally, and predicted that this figure would increase to ~366 
million by the year 2030 (6). However, these predictions have been well surpassed as there 
are presently ~346 million people suffering from diabetes and projections show that this 
figure will reach in excess of half a billion by 2030 if strategies are not put in place to deal 
with the growing prevalence of diabetes (7).  This gross underestimation is of great concern 
and highlights the fact that diabetes has reached epidemic proportions and requires immediate 
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and urgent attention. Moreover, initially considered a condition associated with relative 
affluence, diabetes is now more prevalent in low- and middle-income countries with a 
predicted 69% increase in incidence from 2000 to 2030 compared to a projected 20% rise in 
developed countries (1). These compelling data led to diabetes earning the title of “global 





The African continent finds itself in a unique situation when viewed in this particular context. 
Already plagued with infectious diseases such as Human immunodeficiency virus-acquired 
immunodeficiency syndrome (HIV-AIDS) and tuberculosis (TB), Africans are facing a 
“dual-burden” of disease where non-communicable diseases such as diabetes and CVD are 
increasing in parallel (8). There are ~14.7 million reported diabetes cases in sub-Saharan 
Africa and this figure is projected to rise by a staggering 98% by 2030 (9). Since diabetes can 
exacerbate HIV-AIDS (10) as well as the development of active TB (11) the situation 
Figure 1. 1 Global diabetes prevalence in 2000 (black) and projections for 2030 (blue) 
shown by geographical area (6). 
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becomes critical. Moreover, 80% of all diabetes-related deaths occur in low- and middle-
income countries such as those typically found in Africa (4). Furthermore, the progression of 
diabetes on the African continent and other developing countries is heightened by poverty, 
socio-economic circumstances, and increased urbanization, culminating in a host of poor 
lifestyle choices together with the onset of obesity (4) (9). 
 
Obesity remains a key driving force in the development of type 2 diabetes (12) and if current 
trends continue, an estimated 2 billion individuals will be classified as overweight by 2030 
(13). However, in many Asian countries where the prevalence of obesity is relatively low 
there is a surprisingly high incidence of type 2 diabetes (14) (15). This suggests that other 
factors may also play a role in the onset and development of type 2 diabetes (refer to section 
1.4.1 for further discussion). 
 
1.2 DIABETES-ASSOCIATED PATHOLOGIES  
Diabetes is associated with a plethora of micro- and macrovasculature complications 
manifesting in a variety of pathologies including; CVD (16), retinopathy (17), nephropathy 
and neuropathy (reviewed in (18)). This in turn causes an increase in morbidity and mortality 
rates among diabetic patients (19). Since CVD is the leading cause of death worldwide its 
close association with diabetes is of great concern (4). For example, 65% of all diabetes-
related deaths arise from CVD. These statistics highlight the immense challenges encountered 
by diabetic patients, e.g. such individuals have on average a 50% higher chance of all round 
mortality when compared to non-diabetic persons (19).  
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Since the early diagnosis of diabetes attenuates the progression of the associated 
complications and consequently promotes a better patient outcome, it is imperative to 
promote efforts to increase the diagnosis of diabetes (20). This is especially pertinent to the 
diagnosis of pre-diabetes so that treatment regimens can be implemented before debilitating 
and costly complications are allowed time to develop. Such efforts should in turn help reduce 
some of the detrimental social and economic consequences associated with type 2 diabetes 
(reviewed in (19) (21)). 
 
1.3 DIAGNOSIS  
Despite the availability and accessibility of current diagnostic tools a substantial number (30 - 
50%) of individuals remain undiagnosed (22). Furthermore, the prevalence of individuals 
with evidence of complications at diagnosis is worrisome (23) since this causes a tremendous 
number of unnecessary morbidity and mortality cases (2) (24). This supports the idea for 
increased efforts into earlier detection of diabetes (2) (24) since this should promote 
favorable patient outcomes and also be economically beneficial (19).  
 
1.3.1 The Past 
Diabetes was first recognized and described as early as ~600 BC (25). Initially the diagnosis 
thereof relied upon the attraction of ants towards a urine sample, and later the sweetened taste 
of urine (25). Since then considerable advances have been made, e.g. the introduction of 
biochemical assays such as the oral glucose tolerance test (OGTT), the fasting plasma 
glucose test (FPG) and most recently the measurement of glycosylated hemoglobin (HbA1c) 
in erythrocytes (26) (27).  
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Despite these clinical advances, the diagnosis of diabetes remains controversial as it is 
confounded by an on-going global debate regarding the preferred screening methods and 
organization-specific cut-off criteria/ diagnostic thresholds (28). For example, specific cut-off 
criteria have been repeatedly revised and amended by the American Diabetes Association 
(ADA) and the WHO; two leading expert organizations responsible for diabetes diagnosis 
(28) (refer to Table 1.1 for diabetes diagnosis amendments throughout the period 1985 - 
2003). 
 
Table 1.1. WHO vs. ADA diagnostic criteria: 1985  - 2003. 
 OGTT FPG OGTT FPG 
 (mmol/l) (mmol/l) 
 1985 WHO Criteria 1999 WHO Criteria 
Normal 
<7.8 - <7.8 <6.1 
Pre-diabetes 7.8-11.0 - 7.8-11.0 6.1-6.9 
Diabetes ≥11.1 ≥7.8 ≥11.1 ≥7.0 
 1997 ADA Criteria 2003 ADA Criteria 
Normal 
Not endorsed as a 
diagnostic tool 
<6.1 <7.8 <5.6 
Pre-diabetes 6.1-6.9 7.8-11.0 5.6-6.9 
Diabetes ≥7.0 ≥11.1 ≥7.0 
ADA: American Diabetes Association; FPG: Fasting plasma glucose; OGTT: Oral glucose tolerance test; WHO: World Health Organization 
 
1.3.1.1 Glucose based assays - OGTT (impaired glucose tolerance) and FPG (impaired 
fasting glucose) 
Since hyperglycemia is the primary biochemical hallmark of diabetes, the diagnosis thereof 
has for decades relied upon the measurement of glucose levels using either the OGTT or the 
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FPG test (28). Each test requires an overnight fast with consequent blood glucose 
measurements. The OGTT requires the patient to ingest 75 grams of glucose orally 
whereafter blood glucose levels are measured over a 2 hour period. By contrast, the FPG test 
is a once-off blood glucose measurement (29).  
 
The OGTT and FPG tests are also able to define an intermediate group of individuals whose 
glucose levels do not meet the criteria to be classified as diabetic, but are at a higher risk of 
developing diabetes than those with normal glucose levels (30) (31). This is referred to as 
impaired glucose tolerance (measured by the OGTT) or impaired fasting glucose (measured 
by the FPG test) (30). Such patients are referred to as having pre-diabetes and are at high risk 
of developing diabetes (30). While the WHO has traditionally favored the use of the OGTT 
the ADA has given preference to the FPG test, only endorsing the use of the OGTT to 
diagnose diabetes in 2003 (32). These tests were amended and revised throughout the period 
1985 - 2010 in order to increase the specificity and sensitivity of diabetes diagnosis (28) (30) 
(see Table 1.2). Although both tests have consistently been used to diagnose diabetes for 
decades, there is less than 100% concordance between the 1999 WHO and 2003 ADA 
diagnostic criteria (33). 
 
1.3.1.2 The controversial inception of HbA1c 
In 2009 an International Expert Committee (IEC) convened by the ADA authorized HbA1c 
as an additional tool for the diagnosis of diabetes (27). That was acknowledged two years 
later by the WHO (34). However, HbA1c is not officially regarded as superior to blood 
glucose methods, but instead provides an alternative thereby adding further complexity to the 
already multi-faceted diagnosis of diabetes (27). The HbA1c test measures the level of 
glycated hemoglobin (glucose attached to various amino groups of hemoglobin) over the 120 
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day lifespan of an erythrocyte, reflecting a more stable, average measurement of glucose 
regulation (35). The IEC recommended a diagnostic cut off value of >6.5% to diagnose 
diabetes and this was later amended to include a pre-diabetic category (5.7 – 6.4%) (27).  
 
1.3.2 The Present 
1.3.2.1 Current ADA and WHO diagnostic criteria 
Irrespective of the on-going global debate surrounding the diagnosis of diabetes, the 2010 
ADA guidelines and 2011 WHO report together approve the use of the OGTT, FPG test and 
HbA1c assay to accurately diagnose diabetes (34). Notably, the pre-diabetes criteria differ 
between the two organizations with the WHO disregarding HbA1c entirely as a tool to 
identify this condition (36). Neither institution endorses the use of one test over another, and 
the decision regarding the most appropriate assay to use is left exclusively to the discretion of 
healthcare professionals (37). 
 








Normal <7.8 <7.8 
Pre-diabetes 7.8-10.9 7.8-10.9 
Diabetes ≥11 ≥11 
FPG 
(mmol/l) 
Normal <5.6 <6.1 
Pre-diabetes 5.6-6.9 6.1-6.9 
Diabetes ≥7 ≥7 
HbA1c 
(%) 
Normal <5.7 - 
Pre-diabetes 5.7-6.4 - 
Diabetes ≥6.5 ≥6.5 
ADA: American Diabetes Association; FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin; OGTT: Oral glucose tolerance 
test; WHO: World Health Organization 
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Despite the continual revision and amendment of diagnostic thresholds, incongruity between 
the ADA and the WHO persists, while discordance between the OGTT and FPG test remains. 
For example, in a large epidemiological study only 22% of newly diagnosed diabetics met the 
FPG criteria, 47% the OGTT criteria, and only 30% of individuals fulfilled both sets of 
diagnostic criteria (38). Despite the implementation of HbA1c reference ranges, many studies 
assessed the ability of the HbA1c assay to accurately diagnose diabetes (specificity and 
sensitivity) with various cut-off values yielding conflicting results (39). Moreover, in a study 
employing an HbA1c threshold value of >6.5% to diagnose diabetes only 11.2% of newly 
diagnosed individuals (glucose detection methods) were identified as being diabetic (38). So 
although an HbA1c threshold of >6.5% may demonstrate high specificity there is a trade-off 
with sensitivity, often missing individuals who are truly diabetic (40). Hence an HbA1c level 
of >6.5% used in isolation to diagnose diabetes should be interpreted with caution in order to 
prevent misdiagnosis. For this reason the WHO does not endorse the use of HbA1c to define 
pre-diabetes nor does it eliminate the possibility of diabetes diagnosis with an HbA1c level 
<6.5% (36). 
 
Taken together it is clear that the diagnosis of diabetes is a complex process and cut-off 
criteria need to be constantly reviewed and revised to ensure the accurate and sensitive 
diagnosis of diabetes. Furthermore, no single test appears superior to another as each tool is 
subject to its respective advantages and limitations (refer to section 1.3.2.2) and consequently 
alludes to the use of a combination of available tools. Regrettably, this is not always practical 
within the clinical setting.  
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1.3.2.2 Advantages and limitations of current diagnostic tools 
Many factors can impede the reliability and reproducibility of diagnostic tests and it is thus 
important to consider these. Variability can stem from biological differences, the nature and 
sampling of the specimen, and the particular chemical/ biological assay employed (41). 
  
Although the FPG test is a relatively inexpensive and standardized tool it is limiting since it 
measures a once-off blood glucose reading.  It thereby fails to indicate daily glycemic 
fluctuations and captures only a single aspect of glucose metabolism. By disregarding the 
post-prandial state, abnormal glucose tolerance (indicative of pre-diabetes) is discounted (41). 
Since the FPG test captures only a single “snapshot” of glucose metabolism at a particular 
time, it is subject to large intra-individual variability discrediting its reliability and 
reproducibility (42). In addition, pre-analytical stability of the sample, inconvenience and 
duration of the fast, and patient stress and activity levels may impede the accuracy of the test 
(41). 
  
The OGTT has long been referred to as the “gold standard” of diabetes diagnosis (41) (43). 
Since it measures post-prandial glucose fluctuations it can assess impaired glucose tolerance 
making it an early marker of diabetes – a very attractive property (41). It is also a better 
predictor of diabetes-associated complications than FPG (33) (44). However, it is impractical 
since it requires an overnight fast and availability for more than 2 hours in order to complete 
the test (41). OGTT also exhibits the highest intra-individual variability of all the currently 
available diagnostic tests (42), together with distinct gender differences that further impede 
its reliability (45). 
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Although HbA1c measures average glucose concentrations and does not require an overnight 
fast, it is subject to various other limitations (40). For example, the cost of the HbA1c assay is 
greater than the OGTT and FPG test which limits its global popularity and consequent 
standardization. Although accredited with exceptional specificity it lacks sensitivity and is 
thus not as accurate in diagnosing pre-diabetes as glucose-based methods which reflect the 
variance of glycemia and not merely the mean (36) (40). It is also not recommended as a 
diagnostic tool in a number of clinical conditions (40), where age, ethnicity (46), iron 
deficiency/ overload (47), and HIV-AIDS (48) may impact on HbA1c levels. Indeed, a study 
assessing the value of HbA1c in a South African setting established that it is not a viable 
diagnostic tool in this case (49). 
 
1.3.3 The Future 
Given the current status of diabetes diagnosis and the controversies discussed above, it is 
evident that investigations into novel diagnostic tools are justified. Here the conception of a 
new diagnostic tool, subject to fewer limitations and greater sensitivity, to detect the early 
onset of type 2 diabetes should be a valuable clinical advance. 
 
1.4 ETIOLOGY  
1.4.1 Is it as simple as “eat less, move more”? 
While there exists a robust link between obesity and the development of insulin resistance/ 
type 2 diabetes, individuals with a wide range of body weights can and do develop diabetes 
(12) (50). For example, in many Asian countries where the prevalence of obesity is relatively 
low there is a surprisingly high incidence of type 2 diabetes (51). Obesity is also confounded 
by environmental, ethnic, socio-economic, behavioural, and genetic factors (51-54). Thus 
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INSULIN RESISTANCE  
TYPE 2 DIABETES 
Obesity 
Environment Ethnicity Socio-economic Genetic 
although obesity remains a strong driving force underlying the development of insulin 
resistance and type 2 diabetes, it is not the only risk factor (55). Together these findings show 
that the development of type 2 diabetes is multi-faceted and subject to complex interactions 













While certain environmental factors such as access to a high caloric diet contribute directly to 
the development of obesity and thus insulin resistance/ type 2 diabetes, additional factors are 
independently linked to the development of diabetes (56). For example, industrialization has 
resulted in the promotion of a sedentary lifestyle and a global decrease in physical activity 
that is independently linked to the development and progression of diabetes (56) (57). More 
recently the direct association of environmental agents such as nicotine and certain pollutants 
with the development of type 2 diabetes are receiving increased attention (52). 
 
Figure 1. 2. The development of insulin resistance/ type 2 diabetes is multi-
factorial. 
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A number of epidemiological studies have shown that the risk of developing diabetes differs 
among different racial and ethnic groups, regardless of obesity (58-60). It is well recognized 
that Asians, particularly Asian Indians, who exhibit a relatively low prevalence of obesity 
present with an unexpectedly high incidence of type 2 diabetes (15) (51). This has been 
attributed to having a high abdominal adiposity distribution – an established risk factor for 
the development of type 2 diabetes (61). Accordingly, an individual may be of normal weight 
(defined by BMI), but simultaneously display a “metabolically-obese” phenotype resulting in 
insulin resistance (50) (62). Ethnicity therefore further adds to the complexity of developing 
insulin resistance/ type 2 diabetes independent of obesity (defined by BMI) through the 
concept of the metabolically obese, normal weight (MONW) person. 
 
1.4.1.3 Socio-economic 
A lower socio-economic status (SES) has long been linked to an increase in the prevalence of 
type 2 diabetes as well as various other health risks (53). While the link is often attributed to 
an increase in exposure to diabetes-associated risk factors such as decreased healthcare, 
obesity (cheap, carbohydrate- and fat-rich foods which are nutrient-deprived) and physical 
inactivity, all fuelled by poverty (53), a new relationship between SES and type 2 diabetes is 
emerging, namely chronic inflammation. Here scientists demonstrated that chronic 
inflammation, in response to stress, accounted for up to one third of the association between 
socio-economic disadvantage and the development of type 2 diabetes (63). Thus while a 
decrease in SES may expose individuals to environmental factors/ behavioural choices that 
may promote the development of obesity and consequently type 2 diabetes, SES may also be 
a direct cause of diabetes development through its association with chronic inflammation. 
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The consumption of cheap, nutrient-deprived, carbohydrate- and fat-rich foods is often 
necessary owing to poverty and decreased SES (53). However, many individuals who are not 
exposed to these circumstances continue to make unhealthy lifestyle choices despite knowing 
and understanding the risk factors associated with type 2 diabetes.  
 
1.4.1.5 Genetic 
In addition to the environmental evidence presented above, there is compelling evidence for 
the role of genetics in the pathogenesis of type 2 diabetes (64). The strong genetic component 
is substantiated by the fact that 40% of first degree relatives of patients suffering from 
diabetes will develop the disease themselves, when compared to 6% for the general 
population (54). Studies on monozygotic twins have further confirmed the role of genetics in 
the development of type 2 diabetes, i.e. the concordance rate of developing diabetes between 
monozygotic twins (~70%) is substantially higher than between dizygotic twins (~20%) (65) 
(66).  
 
Additional genetic evidence stems from the high prevalence of diabetes among certain 
populations such as the Asian Indians and Mexican Americans (51, 67). Furthermore, 
monogenic cases of diabetes exist resulting in maturity-onset diabetes of the young (MODY) 
– a clinical subtype of type 2 diabetes accounting for 1-2% of total cases (68). While six 
individual mutations are described to cause MODY (69), polygenic cases of type 2 diabetes 
are far more complex. Since the completion of the human genome project (70), large scale 
genome-wide association studies (GWAS) are being carried out to in order to successfully 
link over 40 loci to the development of type 2 diabetes (71). Despite these successful attempts 
they only account for ~5 - 10% of the observed heritability associated with diabetes (54). 
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Thus a considerable genetic “dark-matter” still needs to be accounted for (64). Indeed, other 
biological explanations for disease susceptibility such as epigenetics (phenotypic variation 
without a change in the primary DNA sequence) and its effect on gene expression also need 
to be considered and assessed in order to obtain a better understanding of the risk for 
developing type 2 diabetes and elucidating the associated heritability (54). Moreover, 
changes in response to type 2 diabetes could aid in the identification of molecular markers 
that may prove valuable in tracking the state and progression of the disease (54) (72). 
Evidently, genetics plays a large but confounding role in the development of type 2 diabetes 
and the susceptibility loci identified thus far merely scrape the surface in the search for the 
missing heritability in type 2 diabetes (64). In addition to the independent contribution of 
genetics to type 2 diabetes, established links between genetics and the predisposition to 
developing obesity likewise exist (54) (73). 
 
Taken together, it is clear that the development of type 2 diabetes is multi-faceted. Ultimately 
obesity remains a robust driving force behind the increasing prevalence of type 2 diabetes. 
For this reason it is important to understand that the simple “eat less, move more” mantra 
associated with obesity may be a gross oversimplification of a complex metabolic disease. As 
presented above there are numerous confounding factors that contribute to the development 
of obesity, demonstrating that the struggle against weight gain and consequent type 2 diabetes 
is a complicated and personal matter. Moreover, the body’s ability to store excess energy, 
that has promoted the survival of our species, is no longer a necessity due to unlimited access 
to a high caloric diet. Consequently our bodies have not had enough time to genetically/ 
metabolically adapt to this “free food” diet further fuelling the obesity epidemic (Figure 1.3) 
(74). 
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1.4.2 Metabolic derangements associated with type 2 diabetes 
It is widely acknowledged that the pathogenesis of type 2 diabetes is not entirely understood 
(69). Despite this many cell culture and animal models have been designed to increase our 
understanding of the progression and development of the disease, each replicating a set of 
genetic and metabolic changes that occur with type 2 diabetes (69) (75). The two most 
common forms of diabetes are type 1 diabetes (decreased insulin production) and type 2 
diabetes (decreased response to insulin), although other rarer cases do exist such gestational 
diabetes and mono-genic cases (76). Type 2 diabetes accounts for 90 - 95% of all diabetes 
cases worldwide and is characterized by diminished insulin signaling and/ or insulin secretion 







TYPE 2 DIABETES 
Figure 1. 3. The etiology of type 2 diabetes defies explanation by a single 
underlying causative agent. 
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1.4.2.1 Insulin resistance and hyperinsulinemia 
Under normal physiological conditions insulin is released from pancreatic β-cells in response 
to a rise in blood glucose concentrations (e.g. with caloric intake) (77). Insulin subsequently 
lowers blood glucose concentrations by 1) increasing glucose uptake in insulin-dependent 
tissues (adipose, skeletal and hepatic) and 2) inhibiting glucose output by the liver 
(gluconeogenesis) and adipocytes (lipolysis), respectively (78). Maintaining glucose 
homeostasis is vital as increased glucose concentrations are harmful to many tissues while 
too low a decrease may result in hypoglycemia and associated complications e.g. comas (79). 
The key metabolic disturbances that occur with type 2 diabetes include: impaired insulin 
signaling; reduced insulin secretion; increased hepatic glucose output/ decreased glycogen 
synthesis and; increased FFA metabolism (lipolysis)/ decreased lipogenesis, although the 
precise underling molecular mechanisms are not yet well defined (69).   
 
In brief, insulin signaling commences when insulin binds to the insulin receptor (IR) and 
consequently phosphorylates a host of substrates including insulin receptor substrate 1 
(IRS1). IRS1 then binds phosphoinositide 3-kinase (PI3K), resulting in the activation of 
pyruvate dehydrogenase kinase (PDK) through its association with phosphatidylinositol- 
3,4,5-triphosphate (PIP3). PDK subsequently activates AKT (protein kinase B) through 
phosphorylation, resulting in a number of downstream effects critical for maintaining glucose 
homeostasis (80) (see Figure. 1.4).  
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GLUT4: Glucose transporter 4; IR: Insulin receptor; IRS1: Insulin receptor substrate 1; PDK: pyruvate dehydrogenase kinase; PIP2/ 3: 
phosphatidylinositol-3,4,5-triphosphate; PI3K: phosphoinositide 3-kinase.   
 
Since glucose is a hydrophilic molecule, specific glucose transporters (GLUTs) are necessary 
for it to penetrate the lipid bilayer and enter the cell (81). AKT phosphorylation ultimately 
results in GLUT4 translocation to the sarcolemma for subsequent glucose uptake into the cell 
(reviewed in (82)). In addition, AKT phosphorylation further contributes to glucose 
homeostasis by controlling hepatic and lipid metabolism by way of influencing glycogen and 





















Figure 1. 4. Molecular mechanisms of insulin signaling and downstream effects on 
glucose metabolism.  
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1.4.2.2 Impaired insulin signaling 
Since insulin signaling involves a series of signaling cascades it may be impaired at many 
points in signal transduction. If insulin signaling is activated by phosphorylation it can 
likewise be inhibited by dephosphorylation. A number of inhibitory phosphatases act on the 
IR and other key modulators of insulin signaling including: SH2-containing tyrosine-protein 
phosphatase (SHP2); phosphatase and tensin homolog 10 (PTEN); protein-tyrosine 
phosphatase 1B (PTP-1B); and suppressor of cytokine signaling 3 (SOCS3), resulting in 
attenuated insulin signaling (82-85) (Figure 1.5). Furthermore, insulin signaling may also be 
diminished by inhibitory serine phosphorylation of IRS1, thereby inhibiting the IRS1/ PI3K 
complex and subsequent activation of AKT (80) (86) (Figure 1.5). Additionally, increased 
FFA metabolism results in impaired insulin signaling (12) (see section 1.4.2.3 for 
mechanism). 
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A number of inhibitory phosphatases are able to modulate insulin signaling at various points in signal transduction (red), while IRS1 serine 
phosphorylation attenuates insulin signaling by preventing IRS1/ PI3K formation (blue). 
GLUT4: Glucose transporter 4; IR: Insulin receptor; IRS1: Insulin receptor substrate 1; PDK: pyruvate dehydrogenase kinase; PIP2/ 3: 
phosphatidylinositol-3,4,5-triphosphate; PI3K: phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog; PTP1B: protein-tyrosine 
phosphatase 1B; SHP2: SH2-containing tyrosine-protein phosphatase; SOCS3: suppressor of cytokine signaling 3 
 
1.4.2.3 Increased hepatic glucose output/ decreased glycogen synthesis 
During times of nutrient excess, AKT is phosphorylated and consequently inhibits glycogen 
synthase kinase 3 (GSK3) which in turn prevents it from inhibiting its substrate, glycogen 
synthase, promoting glycogen synthesis and storage (87) (Figure 1.6 A). However, when 
insulin signaling is diminished AKT is not activated and hence glycogen synthesis is not 
stimulated (87) (Figure 1.6 B). This results in elevated blood glucose concentrations since 
excess glucose is consequently not stored as glycogen. AKT activation further contributes to 
Figure 1. 5. Dephosphorylation results in impaired insulin signaling and disrupts 
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hepatic glucose metabolism since it results in a decrease in transcription of two 
gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G-6-Pase) through the phosphorylation of forkhead transcription factor box 
protein (FOXO) (80) (87) (88) (Figure 1.6 A). As a result, it limits the production of glucose 
through gluconeogenesis (88) (89). Hence when signaling is disrupted, hepatic glucose output 
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A: Under normal physiological conditions AKT is phosphorylated (upon insulin stimulation) and consequently regulates hepatic glucose 
metabolism by: 1)  promoting glycogen synthesis via the inhibition of GSK3 with subsequent promotion of glycogen synthase and 2) 
decreasing hepatic glucose output by phosphorylating FOXO and lowering PEPCK and G-6-Pase transcription. 
B: Diminished AKT phosphorylation promotes hyperglycemia by decreasing glycogen synthesis via the inhibition of the enzyme glycogen 
synthase and increases hepatic glucose output via reduced FOXO phosphorylation with consequent rises in PEPCK and G-6-Pase 
transcription. 
AKT: Protein kinase B; FOXO: Forkhead transcription factor box protein; GLUT4: Glucose transporter 4; GSK3: Glycogen synthase kinase 
3; G-6-Pase: Glucose-6-phosphatase; PEPCK: phosphoenolpyruvate carboxykinase.   
 
Figure 1. 6 A: Phosphorylated AKT promotes glycogen synthesis and inhibits 
hepatic glucose output. B: Impaired insulin signaling results in the inhibition of 
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1.4.2.4 Increased fatty acid metabolism/ decreased lipogenesis 
AKT phosphorylation regulates lipid metabolism by inhibiting lipolysis and promoting the 
storage of glucose as triglycerides through enhanced lipid production (87). Phosphorylated 
AKT promotes lipid biosynthesis through promoting the stability of sterol regulatory 
element-binding proteins (SREBPs) which are transcription factors responsible for the 
upregulation of genes involved in fatty acid synthesis (87). Thus when insulin signaling is 
impaired AKT fails to enhance SREBP stability, thereby inhibiting fatty acid synthesis (87). 
It is also proposed that AKT activation can inhibit lipolysis through the activation of 
phosphodiesterase 3 B (PDE3B) – a gene suggested to inhibit the breakdown of fatty acids 
(90) (91).  
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A: Upon insulin stimulation, phosphorylated AKT enhances fatty acid biosynthesis by inhibiting the breakdown of lipids by activating 
PDE3B and promoting the formation of lipids by increasing SREBP stability. 
B: Attenuated AKT phosphorylation prevents lipid synthesis by decreasing the stability of SREBPs while concurrently increasing the 
breakdown of lipids (via PDE3B inhibition), promoting FFA metabolism.  
AKT: Protein kinase B; FOXO: Forkhead transcription factor box protein; GLUT4: Glucose transporter 4; GSK3: Glycogen synthase kinase 
3; G-6-Pase: Glucose-6-phosphatase; PEPCK: phosphoenolpyruvate carboxykinase; PDE3B: Phosphodiesterase 3 B; SREBPs: Sterol 
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Figure 1. 7 A: Phosphorylated AKT promotes fatty acid synthesis and inhibits 
lipolysis. B: Attenuated insulin signaling results in the inhibition of lipogenesis and 
promotes fatty acid metabolism, thereby augmenting hyperglycemia. 
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Enhanced fatty acid metabolism refers to the increased metabolism of non-esterified fatty 
acids (NEFAs) for energy production and may be the single most important factor 
contributing to the loss of insulin sensitivity with type 2 diabetes (12). Since there is a 
consequential increase in adipocyte mass and number with the development of obesity/ type 2 
diabetes there is a resultant increase in NEFA metabolism (12) (92). Indeed, individuals 
suffering from type 2 diabetes present with increased circulating NEFAs (93). The role of 
NEFAs in insulin resistance was first described exactly 50 years ago by Randle et al. (94). 
Here it was proposed, through the glucose-fatty acid cycle, that glucose oxidation was 
inhibited due to an increase in free fatty acids (FFAs). Increased FFA oxidation results in 
greater acetyl-CoA/CoA and NADH/NAD+ ratios in the mitochondrion. This in turn inhibits 
pyruvate dehydrogenase (PDH) activity causing an increase in cytosolic citrate and a 
consequent decrease in phosphofructokinase (PFK) levels – a key glycolytic enzyme. 
Consequently, upstream glycolytic intermediates such as glucose-6-phosphate (G-6-P) 
accumulate, eventually resulting in the inhibition of hexokinase and an accumulation of 
intracellular glucose and decreased glucose uptake through GLUT4 (94) (95). 
 
It has since also been proposed that decreased glucose uptake rather than altered glucose 
metabolism (described by Randle) may be responsible for fatty acid-induced insulin 
resistance (78).  Here metabolites of FFAs such as acyl-CoAs, ceramides, and diacylglycerol 
(DAG) are proposed to disrupt insulin signaling through the activation of protein kinase C 
(PKC) (Figure 1.8). PKC activation promotes the inhibitory serine phosphorylation of IRS1 
thereby impeding the association of IRS1 with PI3K and ultimately decreasing AKT 
phosphorylation/ activation. The consequences include decreased GLUT4 translocation, 
increased hepatic glucose output and, lipolysis (discussed and explained in sections 1.4.2.1 - 
1.4.2.4) creating a vicious cycle of insulin resistance with consequent hyperglycemia. 
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FFA metabolism leads to the release of DAG which in turn activates PKC. PKC initiates a serine/ threonine cascade resulting in IRS1 serine 
phosphorylation. Since the association of IRS1 and PI3K is dependent on threonine phosphorylation the complex is inhibited resulting in 
diminished insulin signaling. 
AKT: Protein kinase B; DAG: Diacylglycerol; FOXO: Forkhead transcription factor box protein; GLUT4: Glucose transporter 4; GSK3: 
Glycogen synthase kinase 3; G-6-Pase: Glucose-6-phosphatase; IR: Insulin receptor; IRS1: Insulin receptor substrate 1; PEPCK: 
phosphoenolpyruvate carboxykinase; PDK: pyruvate dehydrogenase kinase; PDE3B: Phosphodiesterase 3 B; PIP2/ 3: phosphatidylinositol-
3,4,5-triphosphate; PI3K: phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog; PTP1B: protein-tyrosine phosphatase 1B; 
SHP2: SH2-containing tyrosine-protein phosphatase; SOCS3: suppressor of cytokine signaling 3; SREBPs: Sterol regulatory element-
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Figure 1. 8.  FFAs release DAG which activates PKC and inhibits IRS1/ PI3K association, 
resulting in diminished insulin signaling.  
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While the principal function of the adipocyte is to store excess energy in the form of 
triglycerides and release FFA molecules into circulation as needed, it also fulfils an additional 
important function (77). Here adipocytes release certain hormones and cytokines that play a 
central role in the regulation of insulin signaling (reviewed in (96)). 
 
1.4.2.5 Diminished insulin secretion 
Lower insulin secretion is another key pathophysiological event contributing towards the 
development of type 2 diabetes (80). Insulin resistance and subsequent hyperinsulinemia may 
precede the development of hyperglycemia by years or even decades (97). The pancreatic β-
cells are initially able to compensate for the loss of insulin sensitivity by increasing insulin 
production (12) (98). This in turn allows the body to maintain a blood glucose level within 
the normal, healthy range allowing for a normoglycemic, but hyperinsulinemic state (99). As 
the disease progresses and insulin resistance rises, the large amounts of insulin produced by 
the pancreas are no longer able to maintain glucose homeostasis and blood glucose levels rise 
(100). This results in pre-diabetes, initially characterized by mild hyperglycemia in 
combination with hyperinsulinemia (12) (Figure 1.9). This prolonged state of 
hyperinsulinemia in combination with gluco-lipotoxicity becomes detrimental to β-cell 
function and subsequently insulin levels begin to decline (77). As insulin production 
decreases and insulin sensitivity is further blunted, blood glucose levels are elevated into the 
diabetic range with simultaneous decreases in insulin concentrations (100) (Figure 1.9). 
Eventually the β-cells become completely exhausted and those patients with long established 
full-blown diabetes become dependent on exogenous supplies of insulin in order to maintain 
normal glucose homeostasis (101) (102).  
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Additional causes of insulin resistance include: mutations in the IRS1 protein; severe 











Adapted from (103). 
 
Briefly, insulin resistance in adipocytes, skeletal muscle and the liver contribute to the 
development and progression of hyperglycemia and consequent type 2 diabetes (69). A 
decrease in adipocyte insulin sensitivity prevents the inhibition of lipolysis thereby increasing 
circulating FFAs and subsequently promoting insulin resistance (12) (78) (94) (95). Hepatic 
insulin resistance prevents the storage of glucose as glycogen, and promotes gluconeogenesis 
thereby increasing hepatic glucose output resulting in augmented hyperglycemia (80). 
Skeletal muscle is the major site of glucose disposal (~75%) thereby making skeletal muscle 









Increasing blood glucose concentration 
Figure 1. 9. The natural biochemical progression of type 2 diabetes.  
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Both insulin-dependent (described above) as well as insulin-independent mechanisms 
regulate the uptake of glucose into cells (81). Since glucose is a hydrophilic molecule, 
specific glucose transporters are necessary for glucose to penetrate the lipid bilayer and enter 
the cell (81). As GLUT4 translocation is diminished with insulin resistance/ type 2 diabetes 
there is a consequent global decrease in glucose uptake by insulin-dependent tissues resulting 
in elevated blood glucose concentrations (81). Surplus glucose then enters insulin-
independent tissues by facilitated diffusion, down a concentration gradient (high 
concentration of glucose in the blood vs. low concentration of glucose in the insulin-
independent tissues) causing elevated glucose flux in these tissues (81). A growing body of 
evidence suggests that augmented glucose metabolism promotes oxidative stress production, 
initiating downstream metabolic derangements (105).  
 
1.5 HYPERGLYCEMIA INDUCES OXIDATIVE STRESS 
Progressive hyperglycemia is widely accepted as the single most important factor 
contributing to micro- and macrovascular pathologies associated with type 2 diabetes (106). 
A unifying hypothesis has identified hyperglycemia-induced production of reactive oxygen 
species (ROS) as the primary mechanism behind the associated tissue damage (106). ROS are 
products of normal cellular metabolism and carry out a variety of functions under 
physiological conditions (107). However, with chronic hyperglycemia homeostasis is 
disturbed and the balance between ROS production and its scavenging is disrupted (107). 
Augmented glucose metabolism concurrently increases the production of ROS and impairs a 
number of antioxidant defence mechanisms, resulting in a global increase in oxidative stress 
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(107). An abundance of ROS leads to protein, lipid and DNA damage (108), culminating in 
physiological dysfunction and a host of pathologies including diabetes. 
 
1.5.1 Mitochondrial superoxide production is the primary source of ROS 
The mitochondrion has been identified as the primary source of ROS production during 
hyperglycemia through the uncoupling of the mitochondrial electron transport chain (ETC) 
(reviewed in (79)). Under physiological conditions the body generates energy in the form of 
ATP through the oxidation of pyruvate. Pyruvate enters the tricarboxcylic acid cycle (TCA) 
where NADH and FADH2 are produced in addition to CO2. These reducing equivalents 
subsequently enter the oxidative phosphorylation pathway/ mitochondrial ETC to generate 
ATP. Normally, electron transfer occurs at complexes I, III, and IV moving protons outward 
into the intermembrane space, creating a proton gradient (109). This results in protons 
passively moving back through the mitochondrial inner membrane space into the matrix, 
driving ATP synthase (situated at complex IV) and hence mitochondrial ATP generation 
(109).  ROS (in the form of mitochondrial superoxide [O2•
-]) production occurs naturally at 
complexes I and III of the ETC, although complex II has also recently been implicated in O2•
- 
production (109, 110). Here antioxidants such as superoxide dismutase (SOD) degrade 
volatile oxygen free radicals to hydrogen peroxide (H2O2) that is then converted to water and 
oxygen by catalase (107).  
 
However, cells containing high intracellular glucose levels (e.g. diabetic individuals) have 
higher levels of glucose-derived pyruvate passing though the TCA cycle (109). Hence more 
NADH and FADH2 are produced and shunted into mitochondrial ETC resulting in a higher 
concentration of electron donors that increases the gradient potential across the mitochondrial 
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membrane (109). Once a critical threshold is reached, electron transfer at complex III is 
blocked triggering electrons to accumulate at coenzyme Q (CoQ) (111). CoQ then begins to 
donate electrons to molecular oxygen resulting in the formation of superoxide (109). Since 
hyperglycemia concurrently increases ROS production and inhibits antioxidant defence 














Adapted with permission from (109). 
During times of hyperglycemia, increased glycolysis results in elevated levels of electron donors (NADH and FADH2) entering the 
mitochondrial electron transport chain. This increases the gradient potential across the mitochondrial membrane resulting in defective 
electron transfer and eventual superoxide production. 
ADP: Adenosine diphosphate; ATP: Adenosine triphosphate; CoQ: Coenzyme Q; Cyt C: Cytochrome C; FAD: Flavin adenine dinucleotide 
(oxidized); FADH2: Flavin adenine dinucleotide (reduced); H2O: Water;  NAD+ :Nicotinamide adenine dinucleotide (oxidized); NADH: 
Nicotinamide adenine dinucleotide (reduced); O2•-:superoxide; SOD: Superoxide dismutase; UCPs: Uncoupling proteins. 
 
Although superoxide is believed to be the primary source of ROS, other forms are also 
produced by the mitochondrion under hyperglycemic conditions (107). For example, H2O2 
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Figure 1. 10. Hyperglycemia induces oxidative stress via the uncoupling of the mitochondrial 
electron transport chain.  
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that is usually converted to water and oxygen by the enzyme catalase is inhibited under 
hyperglycemic conditions allowing H2O2 to be converted to various other ROS forms such as 
the hydroxyl ion (·OH) (112).  
 
Hence with insulin resistance and subsequent chronic hyperglycemia, oxidative stress is 
produced via the uncoupling of the mitochondrial electron transport chain. Cells that are 
unable to control intracellular glucose levels, such as those susceptible to diabetic 
complications (113), are exposed to sustained hyperglycemic conditions and consequently 
develop increased levels of hyperglycemia-mediated ROS (114).  Despite the intrinsic 
protective effects of antioxidants such as SOD, catalase, and reduced glutathione, an 
abundance of hyperglycemia-induced ROS persists and ultimately leads to micro- and 
macrovasulature problems that accompany type 2 diabetes (107) (114).  
 
Although mitochondrial-mediated oxidative stress is the primary source of ROS production 
in the etiology of type 2 diabetes, additional sources of oxidative stress also exist such as the 
activation of alternative non-oxidative glucose-utilizing pathways (NOGPs) (to be discussed 
in detail below) and the production of nitric oxide (·NO) via the nitric oxide synthase 
pathway (107). 
 
1.6 HYPERGLYCEMIA-INDUCED SUPEROXIDE PRODUCTION UPREGULATES 
ALTERNATIVE NON-OXIDATIVE GLUCOSE-UTILIZING PATHWAYS 
While glycolysis utilizes the majority of glucose entering the cell, a small amount of glucose 
is metabolized via alternative NOGPs (106) (107). However, with hyperglycemia excess 
glucose is diverted into the alternative NOGPs resulting in their upregulation (106). Increased 
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flux through four of the five minor glycolytic pathways has been implicated in the 
development of diabetes-associated complications (105).  
 
Hyperglycemia-induced activation of NOGPs is thought to be initiated by a single upstream 
metabolic event namely, the overproduction of mitochondrial superoxide (105) (106). Here 
the mechanism put forward is that mitochondrial superoxide induces DNA strand breakage 
resulting in the activation of poly (ADP-ribose) polymerase (PARP) – an enzyme responsible 
for DNA repair (105) (106). In addition to the role PARP plays in DNA repair it has the 
ability to inhibit the activity of the key glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (115). GAPDH inhibition results in the accumulation of upstream 
glycolytic intermediates that are then diverted into the five alternative NOGPs, i.e. 1) the 
polyol pathway, 2) the pentose phosphate pathway (PPP), 3) the formation of advanced 
glycation end products (AGE), 4) activation of PKC and 5) the upregulation of the 
hexosamine biosynthetic pathway (HBP) (106) (Figure 1.11). Moreover, NOGPs may also be 
upregulated due to increased substrate (glucose) availability experienced with hyperglycemia. 
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       Hyperglycemia augments glycolytic flux and increases mitochondrial ROS production. This activates PARP which subsequently 
inhibits GAPDH activity.       GAPDH inhibition results in further accumulation of upstream glycolytic intermediates which are then 
diverted into the five alternative NOGPs.  
AGE: Advanced glycation end products; ETC: Electron transport chain; F-6-P: Fructose-6-phosphate; G-6-P: Glucose-6-phosphate; 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; HBP: Hexosamine biosynthetic pathway; PARP: Poly(ADP) polymerase; PPP: 















Figure 1. 11. Hyperglycemia-mediated superoxide production inhibits GAPDH 
activity resulting in the upregulation of alternative NOGPs. 
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1.6.1 The Polyol Pathway 
Under normal physiological conditions ~3% of total glucose is metabolized by the polyol 
pathway (112). This pathway is a two-part metabolic process where toxic aldehydes are 
converted to inactive alcohols and then further converted to fructose. The primary function of 
the polyol pathway is to reduce toxic aldehydes into inactive alcohols (116).  The reduction is 
accomplished by a family of aldo-keto reductase enzymes with the aid of the reducing agent 
NADPH (116). Under normoglycemia aldose reductase (encoded by aldo-keto reductase 
family 1, member B1 [AKR1B1]) has a low affinity for glucose; however, during 
hyperglycemia increased intracellular glucose concentrations result in augmented polyol flux 
(109). This subsequently increases the reduction of toxic aldehydes to inactive alcohols 
resulting in decreased NADPH availability (106). However, NADPH is also required as a co-
factor for the conversion of oxidized glutathione to reduced glutathione – a potent antioxidant 
(106) (107).  Hence increased flux through the polyol pathway during times of hyperglycemia 
depletes NADPH and further contributes towards oxidative stress by inhibiting the formation 
of reduced glutathione, a potent antioxidant (109). Furthermore, the conversion of inactive 
alcohols (sorbitol) to fructose by sorbitol dehydrogenase may activate PKC through an 
increased NADPH/NAD+ ratio, further exacerbating ROS production (107). (see section 1.6.2 
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A. Aldose reductase converts toxic aldehydes into inactive alcohols using NADPH as a cofactor. B. NADPH is an important cofactor in the 
conversion of oxidized glutathione to reduced glutathione.  
NAD+: Nicotinamide adenine dinucleotide (oxidized); NADH: Nicotinamide adenine dinucleotide (reduced); NADP+: Nicotinamide adenine 
dinucleotide phosphatase (oxidized); NADPH: Nicotinamide adenine dinucleotide phosphatase (reduced); OX: Oxidized; RED: Reduced.    
 
1.6.2 PKC activation 
The PKC family is comprised of at least 11 known isoforms that play a fundamental role in 
serine/ threonine signaling cascades involved in insulin signaling transduction (117). Under 
hyperglycemic conditions enhanced flux through the PKC activation pathway results in an 
increase of the upstream intermediate, dihydroxyacetone phosphate, that is then reduced to α- 
glycerol-phosphate (118). When the latter is conjugated with fatty acids it promotes the 
formation of DAG that subsequently activates PKC (118) (Figure 1.13). PKC may also be 
activated directly by the stimulation of phospholipase C, by the inhibition of DAG kinase 
(112) (119) (Figure 1.13), indirectly by increased flux through the polyol pathway, or by 
altering the activity of AGEs and their receptors (120) (121). PKC has a detrimental effect on 
insulin signaling and promotes hyperglycemia that in turn contributes to enhanced ROS 
production (refer back to section 1.4.2.4). Furthermore, since PKC promotes the activity of 
NADPH oxidase (thereby decreasing NADPH availability), greater PKC activity lowers the 


















Figure 1. 12. Schematic representation of the polyol pathway. 
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1.13). The reduction in antioxidant capacity in combination with increased ROS production, 
via impaired insulin signaling with consequent hyperglycemia, further drives the cell into a 
state of increased oxidative stress. The over activity of PKC is also linked to harmful 












DAG is formed by increases in glyceraldehyde-3-P, the activation of phospholipase C and the inhibition of DAG kinase. Together these 
mechanisms result in the activation of PKC which promotes NADPH oxidase activity and consequently decreases NADPH availability. 
DAG: Diacylglycerol; Glyceraldehyde-3-P: Glyceraldehyde-3-Phosphate; PKC: Protein kinase C; NADPH:  Nicotinamide adenine 




















Figure 1. 13. Schematic representation of the PKC pathway and its activation. 
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1.6.3 Formation of AGEs 
Increased intracellular glucose initiates the formation of advanced glycation end products in 
three distinct ways (125). AGEs arise from: the auto-oxidation of glucose, decomposition of 
the Amadori product (an organic reaction resulting in the rearrangement of a glucose 
molecule), and the non-enzymatic reaction of glyceraldehyde-3-phosphate and 











AGEs: Advanced glycation end products; Glyceraldehyde-3-P: Glyceraldehyde-3-phosphate. 
 
The products of the three above-mentioned reactions namely; glyoxal (from glucose), 3-
deoxyglucosone (from Amadori product) and methylglyoxal (from glyceraldehyde-3-
phosphate and dihydroxyacetone phosphate) then react with amino groups on intra- and 
extracellular proteins to form AGEs (112). The formation of AGE precursors are able to harm 
target cells by three common mechanisms: 1) intracellular proteins that are modified by 
AGEs exhibit altered function, 2) AGE precursors are able to modify extracellular matrix 
















Figure 1. 14. The formation of AGEs and its harmful effects 
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components of target proteins thereby altering its interaction with other matrix components 
and receptors, 3) proteins modified by AGE precursors result in its binding to respective 
receptors (e.g. RAGE) (126) (127). The latter results in the formation of ROS, that in turn 
activates the ubiquitous transcription modulator nuclear factor kappa B (NF-κB) thereby 
further contributing to ROS formation (126). Since AGEs are present in several tissues of 
diabetic patients its formation is considered a major contributor towards the onset of diabetic 
complications (112). 
1.6.4 The Hexosamine Biosynthetic Pathway 
Under normal physiological conditions a small percentage of intracellular glucose (2 - 5%) is 
diverted from glycolysis and shuttled into the HBP, culminating in the assembly of uridine 
diphosphate N-acetyl glucosamine (UDP-GlcNAc) (128). Fructose-6-phosphate is diverted 
from the central glycolytic pathway and converted to glucosamine-6-phosphate by the rate-
limiting enzyme glutamine:fructose-6-phosphate aminotransferase (GFAT a.k.a. GFPT) 
(129).  Glucosamine-6-phosphate is then converted – via a series of reactions – to UDP-
GlcNAc, the end product of this pathway (129). UDP-GlcNAc molecules are able to attach to 
serine/ threonine residues on target proteins resulting in post-translational modifications 
(PTMs) (130). This process is commonly known as O-GlcNAcylation and its upregulation 
during hyperglycemia is strongly correlated with the onset of insulin resistance and other 
diabetic complications (128) (131). The HBP will be discussed in more detail in section 1.7. 
1.6.5 The Pentose Phosphate Pathway 
1.6.5.1 Overview 
Of the five NOGPs, only the PPP is proposed to play a beneficial role under hyperglycemic 
conditions (106). This pathway consists of both an oxidative and non -oxidative branch (132). 
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The first function of the PPP is to produce NADPH (oxidative branch) that plays an 
important antioxidant role and hence the reason this pathway is considered beneficial under 
hyperglycemic conditions (106). The second is to produce ribose-5-phosphate (non-oxidative 
branch) which is essential for nucleic acid biosynthesis and erythrose-4-phosphate (non-
oxidative branch) for the biosynthesis of aromatic amino acids (133). Since the PPP is able to 
catalyze glycolytic intermediates such as fructose-6-phosphate back to pentose phosphatases, 
thereby reducing the concentrations of such intermediates and consequently diverting the flux 
away from the potentially harmful glycolytic pathways (134), it has generated many research 
investigations into its prospective beneficial role to treat type 2 diabetes (135). Increasing 
PPP flux may thus represent an opportunity to decrease ROS generation through the 
production of NADPH, and also potentially down - regulate flux through the above-
mentioned damaging pathways (134). However, regulation of the PPP during times of 
hyperglycemia is controversial in the literature (138), i.e. some reported upregulated PPP 
with diabetes (138), while others demonstrated the opposite (139). Thus further studies are 
required to confirm its protective role under these circumstances. 
 
1.6.5.2 Regulation 
The rate-limiting enzyme of the non-oxidative branch of the PPP is transketolase and it 
catalyzes the reaction of pentose phosphatases to glycolytic intermediates and vice versa 
(132) (Figure 1.15). Since transketolase activity can be enhanced by benfotamine (a natural 
derivative of vitamin B1) altering the flux through the PPP has become a popular research 
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NADPH:  Nicotinamide adenine dinucleotide phosphatase (reduced); NADP+: Nicotinamide adenine dinucleotide phosphatase (oxidized). 
 
Transketolase is encoded by the TKT gene that resides on chromosome Xq28 – a region 
associated with the formation of malignancies (140). In addition to transketolase, two 
transketolase-like proteins, transketolase-like 1 (TKTL1, encoded by TKTL1) and 
transketolase-like 2 (TKTL2, encoded by TKTL2) have been identified in the human genome 
and share a high sequence identity with TKT on both the gene and protein level (141,142). 
The primary sequence difference between TKT and TKTL1 is a deletion in the N-terminus 
(of 38 consecutive amino acids) of the latter, which forms part of the active site in 
transketolase (141). This has sparked several recent debates as to whether TKTL1 protein in 
fact does hold transketolase activity (143) as was previously hypothesized (141). TKTL1 has 
recently been implicated in a wide variety of cancers – of which altered glucose metabolism 
is a hallmark – where its expression level has successfully been used as a marker for 
















Figure 1. 15. Schematic representation of the PPP. 
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1.6.6 The activation of minor glycolytic pathways - recapped  
The activation of alternative NOGPs is believed to be initiated by a single upstream 
metabolic event namely, mitochondrial superoxide overproduction (105) (106). 
Hyperglycemia results in augmented superoxide production which consequently induces 
DNA damage and in turn activates PARP (105). In addition to DNA repair, PARP inhibits 
the activity of the central glycolytic enzyme GAPDH (115), resulting in the accumulation of 
upstream glycolytic intermediates (106). Such intermediates are then shunted into five 
alternative glucose-utilizing pathways (106). Furthermore, flux through these pathways can 
also be augmented due to an increase in substrate (glucose) availability under hyperglycemic 
conditions, i.e. independent of GAPDH inhibition. Increased pathway flux subsequently 
results in ROS overproduction and a weakening in antioxidant capacity, leading to increased 
oxidative stress (107). The HBP has also been independently linked to the development of 
insulin resistance and type 2 diabetes (128). Despite the current lack of mechanistic detail 
linking the upregulation of alternative NOGPs to diabetes-associated pathologies, it is clear 
that these pathways are intertwined and that the activation of one detrimental pathway may 
stimulate the activation of others, resulting in a vicious feed-forward cycle of ROS 
production and accumulated cellular damage.  
 
Since the HBP is not only upregulated with hyperglycemia, but has also been 
independently linked to the onset of insulin resistance and has the ability to execute 
cellular responses according to the nutritional status of the cell, it was the primary 
pathway under investigation in this study and will accordingly be discussed in full detail 
below. 
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1.7 THE HEXOSAMINE BIOSYNTHETIC PATHWAY: A REVIEW 
The HBP is a fuel sensing pathway that modulates a significant number of cellular processes 
in response to the nutritional status of the cell, an action vital for cellular energy homeostasis 
(146). Such regulation is achieved through the PTM (by addition of O-GlcNAc molecules) of 
serine and/ or threonine residues of target proteins (147). Importantly, the HBP represents the 
amalgamation of glycolytic, amino acid, fatty acid, and nucleotide metabolism allowing for 
increased sensitivity towards the overall nutritional status of the cell (148) (149). Under 
physiological conditions ~2 - 5% of glucose is redirected from the primary glycolytic 
pathway into the HBP (128), where it is proposed to play a protective role in the cell against a 
wide variety of stress stimuli (150).  
 
The HBP diverts from the main glycolytic pathway when fructose-6-phosphate is converted 
to glucosamine-6-phosphate by the rate-limiting enzyme GFAT (129). Glucosamine-6-
phosphate is then converted – via a series of reactions – to UDP-GlcNAc, the HBP end 
product (129).  UDP-GlcNAc subsequently serves as a substrate for the dynamic attachment 
of O-GlcNAc moieties to the hydroxyl groups of serine and/ or threonine residues of target 
proteins – a process commonly known as O-GlcNAcylation (147) (Figure 1.16). The O-
GlcNAc modification is dynamic, reversible and tightly regulated by only two known 
enzymes, O-linked β-N-acetylglucosamine (GlcNAc) transferase (O-GlcNAc transferase, 
OGT) and  β-N-acetylglucosaminidase (O-GlcNAcase, OGA) that catalyze the addition and 
removal of O-GlcNAc moieties, respectively (Figure 1.16). Glucosamine is better able to 
increase levels of UDP-GlcNAc since it enters the HBP downstream of the rate-limiting 
enzyme GFAT (128) (151) (Figure 1.16). This dynamic and reversible modification is fast 
emerging as a key regulator of a wide variety of cellular processes; consequently 
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perturbations in O-GlcNAcylation have been associated with a number of pathophysiological 














The HBP (pink) diverts from glycolysis (orange) when fructose-6-phosphate is converted to glucosamine-6-phosphate by GFAT, the rate-
limiting enzyme. The HBP culminates in the attachment/ removal of O-GlcNAc moieties onto target proteins by OGT and OGA, 
respectively. The HBP has the ability to integrate additional metabolic inputs including amino acid metabolism (purple), fatty acid 
metabolism (green), and nucleotide metabolism (blue). 
G-6-P, glucose-6-phosphate; F-6-P, fructose-6-phosphate; GFAT,glutamine:fructose-6-phosphate amidotransferase; GlcN-6-P, 
Glucosamine-6-phosphate; GlcNAc-6-P, GlcNAc-6-phosphate; GlcNac-1-P, GlcNAc-6-phosphate; UTP, uridine triphosphate; UDP-


























Figure 1. 16. The HBP represents an amalgamation of different metabolic inputs. 
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1.7.1 Experimental evidence links the HBP to insulin resistance and type 2 diabetes 
1.7.1.1 Insulin resistance 
The association between the HBP and insulin resistance was first described by Marshall et al. 
in 1991. Here a marked decrease in insulin sensitivity was observed in isolated rat adipocytes 
when cells were exposed to high glucose concentrations and glucosamine, respectively, in the 
presence of insulin. This effect was reversed by reducing HBP flux – by using GFAT 
inhibitors (128). Numerous studies (cell culture and animal models) link the HBP to the 
development of insulin resistance. For example, transgenic mice overexpressing GFAT in 
both skeletal muscle and adipose tissue develop insulin resistance (153-155). Moreover, 
elevation of intracellular O-GlcNAc levels by either OGT over-expression or OGA inhibition 
also resulted in the manifestation of insulin resistance (153) (156-158).  
 
1.7.1.2 Type 2 diabetes 
A small subset of studies have linked alterations in the HBP with clinical type 2 diabetes. 
Here two studies demonstrated O-GlcNAcylation of target proteins occurs in a glucose-
responsive manner and that there were significant differences between control, pre – diabetic 
and diabetic individuals for global O-GlcNAcylation and OGA protein expression (43) (159). 
A mutation in the OGA gene has also been implicated in the development of type 2 diabetes 
in the Mexican American population, further implicating altered HBP flux in the 
development of type 2 diabetes (67). Thus there is strong support for the link between 
increased HBP flux and the development of insulin resistance, and the underlying mechanism 
responsible for this causal link appears to be aberrant phosphorylation (160).  
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O-GlcNAcylation is a dynamic and reversible PTM and exhibits complex and extensive 
cross-talk with phosphorylation since they regularly compete for many of the same binding 
sites on target proteins (160). For example, in a study where over 700 phosphorylation sites 
were monitored after a 3-fold increase in global O-GlcNAcylation, the phosphorylation 
activity at almost every site was significantly altered in response to O-GlcNAc modification 
(161). Furthermore, O-GlcNAcylated or phosphorylated residues can be in nearby proximity 
to one another and sterically hinder the attachment of the other modification (160). O-
GlcNAcylation possesses the ability to rival phosphorylation and disrupt/ interfere with vital 
phosphorylation signaling cascades – a concept known as the “Yin-Yang hypothesis” (162). 
Therefore during times of hyper O-GlcNAcylation the attachment of O-GlcNAc moieties to 
target proteins disrupts essential phosphorylation cascades, interfering with many vital 
signaling pathways (158). Moreover, the O-GlcNAc status of a protein impacts on protein 
folding, catalytic activity and cellular localization, ultimately affecting its downstream 
function(s) (Reviewed in (163)). Hyper O-GlcNAcylation has therefore been identified as the 
underlying phenotype behind various disease etiologies including; neurodegenerative 
diseases, cancer, and type 2 diabetes (recently reviewed in (146)). 
 
Since insulin signaling is dependent on phosphorylation, it is an example of a metabolic 
pathway exceedingly susceptible to disruption by O-GlcNAcylation (158). In support, studies 
found that increased O-GlcNAcylation inhibits insulin signaling by preventing IRS1 and 
AKT phosphorylation by O-GlcNAc modification (164). More recently it was found that 
after insulin stimulation, PIP3 recruited OGT from the nucleus to the sarcolemma where O-
GlcNAcylation, rather than phosphorylation, of key insulin signaling molecules was favored 
thereby diminishing insulin signaling (158). This ultimately impacts negatively upon glucose 
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homeostasis (discussed in detail in sections 1.4.2.1 - 1.4.2.4). O-GlcNAcylation of β-cell and 
mitochondrial proteins can also disturb insulin secretion and promote mitochondrial 
dysfunction, respectively, further exacerbating insulin resistance and contributing to glucose 
toxicity (165) (166). These effects also extend to the transcriptional level, e.g. FOXO is 
susceptible to O-GlcNAc modification thereby resulting in increased expression of 
gluconeogenic genes together with greater hepatic glucose output (167). The profound effect 
O-GlcNAc has on insulin signaling is only beginning to unravel (146). 
 
While the similarity between O-GlcNAcylation and phosphorylation is striking it must be 
noted that while phosphorylation is controlled by hundreds of kinases and phosphatases, O-
GlcNAc cycling is under the control of only two enzymes (168).  
 
1.7.3 HBP Regulation 
O-GlcNAcylation is under the stringent control of two evolutionary conserved enzymes, 
OGT and OGA (168). OGT is responsible for the attachment of a single O-GlcNAc molecule 
to the hydroxyl groups of serine/ threonine residues on target proteins while OGA catalyzes 
the removal of O-GlcNAc moieties from modified proteins (168). 
 
1.7.3.1 OGT 
OGT catalyzes the attachment of O-GlcNAc moieties to over 1000 nuclear and cytoplasmic 
target proteins (146). These include proteins involved in cell signaling, transcription, 
translation, the cell cycle and many more (160) (169). OGT is found in nearly all living 
organisms from plants to higher mammals (170), is expressed in all tissue types examined 
thus far, and exhibits high species homology. The human OGT gene resides on the X 
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chromosome at position Xq13.1 (171) and the deletion or disruption thereof has proven lethal 
(as demonstrated by OGT knock-out studies (172)). Although OGT is encoded by a single 
highly conserved gene in mammals, alternative splicing results in three distinct isoforms: 
nuclear-cytoplasmic OGT (ncOGT); mitochondrial OGT (mOGT) and short OGT (sOGT) 
(171) (173) (174). The three isoforms share an identical C-terminal domain that confers 
catalytic activity, but differ in their N-terminal domain regarding the number of 
tetratricopeptide (TPR) domains (168). The TPR domains consist of 34 highly conserved 
consecutive amino acids that are repeated between 3 - 12 times and mediate OGT substrate 
specificity and localization to different subcellular compartments (160) (175). The expression 
of each isoform differs among various tissues and cell types, suggesting that different 
isoforms may have distinct functions (176). Since a single enzyme is exclusively responsible 
for the attachment of O-GlcNAc moieties to thousands of target proteins with no obvious 
consensus sequence, OGT regulation remains intriguing and is yet to be fully elucidated 
(177). However, OGT is also regulated in a number of other ways including: its binding to 
lipids; phosphorylation; and auto-O-GlcNAcylation, albeit their mechanisms remain vague 
(163). As the tools used for the detection of O-GlcNAc become more sensitive and more O-
GlcNAc modified proteins are identified (146), it becomes clear that the regulation of OGT 
activity and substrate specificity is highly complex and still poorly understood (163). 
 
1.7.3.2 OGA 
OGA is derived from a single highly conserved gene mapping to position 10q24.1 - q24.3. 
OGA and meningioma expressed antigen 5 (MGEA5) were shown to be encoded by the same 
gene (178). OGA has at least two know alternative spliced forms, one of > 100 kDa and the 
other shorter ~70 kDa isoform (168). Little is known about the different functions or 
localization of these two OGA isoforms, although the larger isoform appears to display 
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greater catalytic activity (179). Since OGA is able to bind thousands of diverse proteins its 
regulation – as with OGT – has attracted interest (168). 
 
1.7.3.3 GFPT1 and GFPT2 
In addition to the direct regulatory role that OGT and OGA play in O-GlcNAc cycling, 
GFAT is responsible for flux through the HBP, ultimately affecting UDP-GlcNAc 
concentrations – the substrate for O-GlcNAcylation (151). GFAT is considered the rate-
limiting enzyme of the HBP owing to feedback inhibition by the product itself (glucosamine-
6-phosphate) and the end product UDP-GlcNAc (151). GFAT is highly conserved among 
species and is regulated on both a post-transcriptional and post-translational level (148) 
(180). The enzyme is transcribed by two distinct genes, GFPT1 (chromosome 2p13) (181) 
and GFPT2 (chromosome 5q34 - q35) (182) with differing tissue distributions, raising the 
possibility that they may have distinct roles in the development of diabetic complications 
(183).  Indeed, both genes and their respective enzymes were previously implicated in the 
pathogenesis of type 2 diabetes. Here diabetic patients exhibited increased GFPT2 mRNA 
levels in lymphocytes (184), while they found augmented GFAT activity in skeletal muscle 
(185). (also refer back to section 1.7.1.1 for additional cell culture and animal model studies). 
 
Despite O-GlcNAcylation being a ubiquitous PTM with far reaching biological implications, 
it is essentially controlled by only three regulatory enzymes (GFAT, OGT and OGA) 
encoded for by four genes (GFPT1; GFPT2; OGT and OGA). This singularity in combination 
with the global disposition of the O-GlcNAc modification highlights the critical and 
fundamental nature of O-GlcNAcylation.  
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Type 2 diabetes has reached epidemic proportions and its association with diseases such as 
CVD results in increased morbidity and mortality rates (16). Alarmingly, diabetes prevalence 
is estimated to double over the next 20 years (7). 
 
Despite the availability and accessibility of current diagnostic tools, diabetes remains 
relatively poorly diagnosed, especially in poorer countries (22). Moreover, the number of 
patients presenting with diabetes-associated complications at diagnosis is unacceptable (23). 
The controversies surrounding specific diagnostic thresholds in combination with the 
shortcomings of each assay highlights the need for investigation into novel diagnostic 
concepts to assist with the earlier and more efficient detection of type 2 diabetes.  
 
Hyperglycemia, the biochemical hallmark of diabetes, promotes the formation of ROS via the 
uncoupling of the mitochondrial ETC (106). Consequently flux through the five non-
oxidative minor branches of glycolysis is elevated resulting in diabetes-associated micro- and 
macrovasculature pathologies (106). This sets the stage for our hypothesis: 
 
1.9 HYPOTHESIS 
Since flux through the NOGPs is increased in response to hyperglycemia, we hypothesize 
that genes encoding the rate-limiting enzymes of each respective pathway will be 
differentially expressed between control, pre-diabetic and diabetic individuals. Moreover, 
differential gene expression in response to augmented glucose flux may represent an 
exploratory avenue in the search for a novel diagnostic tool(s) for type 2 diabetes. 
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1.10 AIMS AND OBJECTIVES 
• Recruit volunteers and acquire blood specimens representing a variety of fasting 
blood glucose levels, from normal to pre-diabetic and diabetic. 
• Characterize individuals according to ADA and WHO criteria based on fasting 
plasma glucose and HbA1c levels, respectively. 
• Design and optimize seven primer pairs for the genes under investigation. 
• Extract mRNA from volunteers and measure leukocyte mRNA transcript levels of: 
GFPT1; GFPT2; OGT; OGA; TKT; TKTL and AKR1B1 employing quantitative real-
time PCR (qPCR). 
• Determine differences in mRNA transcript levels between control, pre-diabetic and 
diabetic individuals. 
 
In doing so we hope to make a significant scientific contribution to the advancing field of 
O-GlcNAcylation and its role as a candidate in the search for a novel diagnostic tool for 
type 2 diabetes. Furthermore, we hope to identify additional biomarkers that are 
differentially expressed with the onset of type 2 diabetes mellitus. 
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2. EXPERIMENTAL PROCEDURES 
2.1 SUBJECT RECRUITMENT AND CHARACTERIZATION 
This study was accepted by the Committee for Human Research at Stellenbosch University 
(reference number: S12/03/074) and was carried out according to the ethical guidelines and 
principles of the International Declaration of Helsinki, the Medical Research Council Ethical 
Guidelines for Research in South Africa, and the South African Guidelines for Good Clinical 
Practice. Experimental design and execution was carried out according to the Minimum 
information for publication of quantitative real-time PCR experiments (MIQE) guidelines 
(186). Volunteers (n = 60; n=20 Mixed Ancestry, n=40 Caucasian) were recruited from two 
neighboring metropolitan regions, namely Stellenbosch and Paarl (Western Cape, South 
Africa). All recruited participants were personally informed about the study and were 
requested to sign a written consent form detailing the study aims and procedures. 
 
Due to the aforementioned discrepancies surrounding the diagnosis of type 2 diabetes, we 
grouped participants according to their FPG levels (ADA and WHO criteria) and their HbA1c 
levels, respectively. Since the WHO does not endorse the use of HbA1c to differentiate 
between pre-diabetes and diabetes, patients classified according to HbA1c levels were done 
so using the ADA criteria. Thus each participant was assigned to one of three groups: control; 
pre-diabetic; or diabetic according to three different diagnostic criteria (refer to Table 2.1). 
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Table 2. 1. Subject characterization 






5.6 - 6.9 mmol/l 
6.1 - 6.9 mmol/l 





ADA, American Diabetes Association; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin.          
 
Table 2. 2. Summary of subjects’ details 
  
Controls Pre-diabetic Diabetic 
Sample size 30 14 16 
Age (years)* 50 ± 2.3 55.4 ± 4 54.8 ± 2.4 
Gender M/F 6/24 7/7 6/10 
Ethnicity MA/C 7/23 6/8 7/9 
FPG (mmol/l)* 5 ± 0.07 6.3 ± 0.1 10 ± 0.8 
HbA1c (%)* 5.6 ± 0.08 6.6 ± 0.2 8.7 ± 0.5 
Insulin (mIU/l)* 9.1 ± 1.1 14.3 ± 3.6 32.3 ± 11.5 
C, Caucasian; F, Female; FPG, fasting plasma glucose; M, Male; MA, Mixed Ancestry 
* Values expressed as mean ± SEM 
 
 
2.2 SPECIMEN COLLECTION 
Whole blood samples were collected from participants, under fasting conditions, by 
venipuncture into specified tubes provided by PathCare, Stellenbosch (Western Cape, South 
Africa).  Clinical measurements included: fasting blood glucose (4 ml potassium oxalate/ 
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sodium fluoride tube), HbA1c (4 ml EDTA tube), insulin (5 ml serum separating tube), C-
reactive protein (5 ml serum separating tube) and homocystein (4 ml EDTA tube).  For 
molecular studies, collected blood samples (4 ml EDTA tube) were stored on ice while 
transported, and total RNA extracted within 3 hours of sample collection.   
 
2.3 RNA EXTRACTION & PRECIPITATION 
Total RNA was extracted using the QIAamp RNA Blood Mini kit in combination with the 
RNase-Free DNase set (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
To confirm the quality and quantity of extracted RNA, samples were subjected to agarose gel 
electrophoresis and spectrophotometry, respectively. A 2% (w/v) RNase-free agarose gel was 
prepared using 1X TBE buffer (1m M EDTA, 90 mM Tris, 90 mM boric acid dissolved in 1L 
RNase-free water) and 0.01% (v/v) ethidium bromide (EtBr). The gel was loaded with 2.5 µl 
of sample RNA, stained with 1X RNA loading dye (Fermentas, ThermoFisher Scientific, 
Waltham, MA, USA) and 5 µl of High Range RiboRuler RNA ladder (Fermentas, 
ThermoFisher Scientific, Waltham, MA, USA) respectively,  after being heated at 70ºC for 5 
min in a 2720 thermal cycler (Applied Biosystems, Foster City, CA, USA). Electrophoresis 
proceeded for 1 hour at 120 V in 1X TBE buffer where after the image was visualized using 
ultra violet light on a Multigenius BioImaging System (Syngene, Cambridge, UK). 
Additionally, each RNA sample was subjected to spectrophotometry (NanoDrop® ND-1000 
spectrophotometer V3.0.1, NanoDrop Technologies, Wilmington, DE, USA) in order to 
determine the respective concentrations and A260/A280 purity ratios. Samples with an 
A260/A280 ratio of <1.8 were discarded. Samples were stored at -80ºC (in 3 volumes of 
100% ethanol) until all 60 samples had been collected. 
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RNA precipitation was performed using a standard sodium acetate protocol. Samples were 
removed from the  -80ºC freezer, allowed to thaw on ice, whereafter sodium acetate was 
directly added to achieve a final concentration of 0.3 M. Afterwards, samples were 
immediately placed at -80ºC for 20 min and subsequently centrifuged at 12, 000 × g at 4ºC 
for 15 min, and the supernatant thereafter discarded. Next, 500 µl of 75% ethanol was added 
and samples were again centrifuged at 12, 000 × g at 4ºC for 15 min. After discarding the 
supernatant, RNA pellets were air-dried and dissolved in RNase-free water (Qiagen, Hilden, 
Germany) to a final concentration of 200 ng/µl. 
 
2.4 cDNA SYNTHESIS 
First strand cDNA synthesis was performed using the Go ScriptTM Reverse Transcription 
System (Promega, Fitchburg WI) according to the manufacturer’s guidelines.   A total of 2.5 
µl of RNA (200 ng/µl) was transcribed to 20 µl of subsequent cDNA. In addition to study 
samples a no template control and a no reverse transcriptase control were included to monitor 
contamination.  Transcribed cDNA was diluted 10-fold in RNase-free PCR grade water 
(Roche Diagnostics, Mannheim, Germany) in order to create a surplus of sample cDNA. 
cDNA samples were stored at -20°C and expression levels measured within 1 week. All 
target gene were run using 10-fold diluted cDNA, except GFPT1 and GFPT2 which were run 
using concentrated cDNA (prior to performing the 10-fold dilution). 
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2.5 GENE EXPRESSION ANALYSIS 
2.5.1 Quantitative real-time PCR 
2.5.1.1 Oligonucleotide Primer design 
Although various detection chemistries are available for gene expression studies, SYBR 
Green I dye was chosen for its sensitivity and reduced running costs (187). Despite these 
advantages an impediment of SYBR Green 1 technology is its ability to bind to all double-
stranded DNA in a non-specific manner (187) (Figure 2.1A). This increases the chance of 
false positives since the dye will bind to specific and non-specific double stranded PCR 
products. Due to this phenomenon great precautions had to be taken when designing primers. 
This was important to ensure that the fluorescent signal being detected was indeed from the 
target gene and not from non-specific double stranded PCR products, contaminating genomic 











A. Reaction set up: SYBR Green I dye binds to all dsDNA non-specifically and consequently fluoresces. B. Pre-incubation/ elongation: 
an increase in temperature causes dsDNA to denature and SYBR Green I to be released resulting in a decreased fluorescent signal. C. 
Elongation: Primers anneal and dsPCR product is formed causing SYBR Green I to bind. D. End of elongation: SYBR Green I is bound to 
all amplified dsPCR product with maximum fluorescence proportional to the amount of PCR product produced. A fluorescence reading is 
obtained at this point. 
Figure 2. 1. A graphic representation of SYBR Green I detection chemistry. 
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Reference sequences for all genes investigated herein were obtained from the Ensembl 
database (www.ensembl.org).  Subsequently, primer pairs were designed using PrimerQuest 
software (Intergrated DNA Technologies) which is an open resource and can be accessed at 
https://eu.idtdna.com/PrimerQuest/Home/Index. Since contaminating gDNA remains an 
undesired reality in qPCR, primers were designed to anneal to two consecutive exons with an 
intron spanning >1 kb between the exons. Consequently, only cDNA from mRNA transcripts 
would be amplified and not transcripts from larger contaminating gDNA, allowing for an 
accurate reading of target gene expression levels. In order to eliminate the presence of primer 
dimers, primer self-complementarity was assessed. Finally, all sequences were entered into 
NCBI BLAST in order to evaluate whether the designed primer sequences would indeed bind 
to the gene of interest, and consequently amplify the target gene, and to check if the primer 
sequence shared homology with any non-specific targets which would cause the 
amplification of undesired PCR products. Once all the above specifications were met for each 
primer pair, primers were ordered from Inqaba Biotech (Pretoria, South Africa). Primer pairs 
for Beta actin (ACTB), and Ribosomal protein 37A (RPL37A) had been previously designed 
(188). Refer to Table 2.3 for primer sequences.  
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Table 2. 3. Primer sequences and optimal PCR conditions for the amplification of synthesized cDNA 
HUGO 
nomenclature 




























































R TTCGCAGCGCCTCTGATAGATGTT 60.5 
*Primers previously designed (188).   
5’: 5-prime; 3’:  3-prime; °C: degrees Celsius; ACTB: β-actin; AKR1B1: Aldo-keto reductase family 1, member B1; bp: base pairs; F: Forward; GFPT1: glutamine:fructose-6-phosphate amidotransferase 1; GFPT2: 
glutamine:fructose-6-phosphate amidotransferase 2; GUS: β-glucuronidase; OGA: O-GlcNAcase; OGT: O-GlcNAc transferse; R: Reverse; RPL37A: ribosomal protein L37a; TKT: Transketolase; TKTL1: 
Transketolase-like protein 1; TA: Annealing temperature; TM: Melting temperature. 
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2.5.1.2 Optimization and standard curve generation 
Random cDNA samples were used to establish the optimal primer conditions (refer to Table 
2.3). Annealing temperature, cycle number and primer concentration were manipulated in 
order to optimize target gene amplification. To confirm that the PCR conditions were indeed 
optimal a melt-curve analysis was performed to ensure that one discreet peak was detected, 
since this indicated that only one product was being amplified. To confirm that this product 
was the target gene, and not additional non-specific product/ primer dimer, samples were 
subjected to agarose gel electrophoresis followed by UV imaging allowing for confirmation 
of the expected product size. 
 
Standard curves were generated for each target and reference gene examined. For this, 
random control samples were amplified, pooled and purified using the GenElute PCR clean 
up kit (Sigma Aldrich, St. Louis, MO, USA) according to the supplied protocol. 
Subsequently, the concentration of the pooled product was measured using 
spectrophotometry (NanoDrop® ND-1000 spectrophotometer V3.0.1, NanoDrop 
Technologies, Wilmington, DE, USA). To generate standard curves the diluted product was 
further serially diluted in RNase-free PCR grade water over a concentration range of 100 - 10-
5. To produce a reliable standard curve for each gene, the product was amplified in replicates 
of 5 for each dilution point over the entire concentration range. The serial dilutions used to 
generate the standard curves were stored at -20ºC and used for validation of imported 
standard curves. Efficiency and slope values for the standard curves generated are presented 
in Table 2.4.  
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Table 2. 4. Standard curve statistics 
ACTB: β-actin; AKR1B1: Aldo-keto reductase family 1, member B1; GFPT1: glutamine:fructose-6-phosphate amidotransferase 1; GFPT2: 
glutamine:fructose-6-phosphate amidotransferase 2; GUS: β-glucuronidase; OGA: O-GlcNAcase; OGT: O-GlcNAc transferse; R: Reverse; 
RPL37A: ribosomal protein L37a; TKT: Transketolase; TKTL1: Transketolase-like protein 1. 
 
2.5.1.3 Amplification of cDNA Sequences 
Target gene amplification was carried out on the Roche LightCycler 480 system in 10 µl 
reactions. Each reaction contained 2 µl of 2x Lightcycler® 480 SYBR Green I Master, 0.5 
pmol of each respective forward and reverse primer, and 1 µl of the corresponding cDNA 
sample. Samples were run in triplicate on two separate occasions each time employing a 
negative control, no template control, no reverse transcriptase control and the respective 
standard curve serial dilution to validate the PCR efficiency and calculate the relative sample 
concentrations. A calibrator was also employed in order to eliminate inter-run variability 
(Refer to Figure 2.2 for an example of plate setup). The reactions were cycled with a pre-
incubation step for 10 min at 95ºC; amplification for 15 sec at the annealing temperature (TA) 
(see Table 2 for optimal TA and cycle number); elongation for 20 sec at 72ºC. Fluorescence 
was measured at the end of the elongation phase at 72ºC. 
Gene  Efficiency Slope 
ACTB 1.99 -3.34 
AKR1B1 1.96 -3.43 
GFPT1 1.95 -3.44 
GFPT2 1.97 -3.40 
GUS 2.00 -3.20 
OGA 1.91 -3.50 
OGT 1.99 -3.32 
RPL37A 1.98 -3.37 
TKT 1.98 -3.36 
TKTL1 1.98 -3.37 
Stellenbosch University  http://scholar.sun.ac.za













NC, negative control; NRT, no reverse transcriptase control; NTC, no template control; STD, standard. 
 
2.6 DATA AND STATISTICAL ANALYSIS 
Standard curves were imported into subject recruit sample runs and used to calculate the 
relative concentrations for each target gene, respectively. Relative concentration values were 
averaged per patient sample and normalized to a calibrator. The relative levels of target gene 
expression were normalized against GUS, ACTB and RPL37A expression, respectively.  This 
was carried out in two independent experimental runs and the values generated from rounds 1 
and 2 were averaged and used for downstream statistical analyses. One-way analysis of 
variance (ANOVA) was used to determine differences in gene expression ratios between 
normal, pre-diabetic and diabetic individuals, followed by two Bonferroni post hoc tests. One 
that compared all pairs of columns and one that compared selected pairs of columns (denoted 
with            ). All statistical analyses were performed using GraphPad Prism version 5.01 
(GraphPad Software Inc, San Diego, CA, USA). P values < 0.05 were recognized as 























































































































Figure 2. 2. Graphical representation of a 96-well LightCycler plate setup. 





















3. RESULTS  
3.1 INVESTIGATION INTO THE HBP 
Here we measured OGA, OGT, GFPT1 and GFPT2 mRNA transcript levels using qPCR with 
SYBR Green 1 detection chemistry. Genes under investigation were normalized to three 
individual reference genes (GUS, ACTB and RPL37A) in order to validate findings. A 
conclusion was drawn if two out of three reference genes presented similar results. Study 
participants were characterized according to: 1) FPG levels, ADA criteria; 2) FPG levels, 
WHO criteria and 3) HbA1c levels, ADA criteria.  
3.1.1 Attenuated OGA expression is associated with diabetes 
3.1.1.1 Reduced OGA expression with increased fasting blood glucose levels (ADA) 
We firstly investigated the mRNA transcript levels of OGA in pre-diabetic and diabetic 
individuals that were characterized according to FPG levels (ADA criteria). By employing 
the use of three reference genes we concluded that decreased OGA expression levels 
accompany diabetes. Both GUS and ACTB normalized data demonstrated a decrease in OGA 
expression levels between control and diabetic individuals of 33 ± 7.8% and 31.7 ± 7.5%, 
respectively (Figure 3.1 A, B). Additionally, OGA normalized to GUS was able to distinguish 
between pre-diabetic and diabetic volunteers with a decrease in OGA expression of 24.3 ± 
8.6% in the diabetic group compared to the pre-diabetics (Figure 3.1 A). While OGA 
normalized to ACTB could differentiate between control and pre-diabetic participants, 
demonstrating a 22.5 ± 9.7% reduction (Figure 3.1 B). RPL37A normalized data did not 
display any statistically significant changes (Figure 3.1 C). 
 
 





Figure 3. 1. Decreased OGA expression in ADA characterized diabetic individuals 
(GUS, ACTB and RPL37A normalized).  
A: Decreased OGA/GUS expression levels in diabetic individuals compared to controls (n=47; *p<0.05; ##p<0.01) and pre-diabetic 
participants (n=47; $p<0.05). B: Attenuated OGA/ACTB expression in both diabetic (n=43; *p<0.05; $$p<0.01) and pre-diabetic (n=43; 
#p<0.05) groups versus control individuals. C. No significant differences were identified in OGA/RPL37A expression levels between the 
three study groups (n=46). 
 
3.1.1.2 OGA expression is able to detect the onset of pre-diabetes (fasting blood glucose, 
WHO criteria) 
When study participants were re-characterized according to the WHO FPG criteria, a 
decrease in OGA expression levels of (34.9 ± 8.2%; 33.9 ± 8%; and 33.4 ± 11%) between 
diabetic and control individuals was observed with normalization to all three reference genes: 
GUS; ACTB and RPL37A, respectively (Figure 3.2 A, B, C). Interestingly, OGA expression 





























































































n = 21 n = 14 n = 12  
n = 20 n = 12 n = 11  
n = 22 n = 12 n = 12  





9.6% and 32 ± 9.8 % reduction) when normalized to GUS and ACTB, respectively (Figure 3.2 




A: Lower OGA/GUS in diabetic (n=45; **p<0.01; ###p<0.001) and pre-diabetic (n=45; #p<0.05) individuals compared to controls. B: 
OGA/ACTB shows decreased levels in diabetic (n=42; *p<0.5; ##p<0.01) and pre-diabetic (n=42; *p<0.05; ##p<0.01) groups when 
compared to control individuals. C: OGA/RPL37A is decreased in diabetics vs. controls (n=45; *p<0.05). 
 
3.1.1.3 OGA expression decreases with increasing HbA1c levels (ADA) 
A similar trend was observed in OGA expression when patients were grouped according to 
HbA1c levels (ADA criteria). All three reference genes indicated a decrease in OGA 





























































































Figure 3. 2. OGA expression is attenuated with increasing FPG concentrations at the 
pre-diabetic and diabetic level (WHO criteria). 
n = 22 n = 10 n = 13  n = 21 n = 10 n = 11  
n = 24 n = 9 n = 12  





diabetic volunteers compared to controls (Figure 3.3 A, B, C). Moreover, contrary to previous 
classifications, OGA normalized to GUS and ACTB were able to distinguish the pre-diabetic 
from the diabetic group showing a decrease of 29.1 ± 6.3% and 32.3 ± 6.6%, respectively 





A: Decreased OGA/GUS expression levels in diabetic vs. control groups (n=44; **p<0.01) pre-diabetic groups (n=44; #p<0.05). B: 
OGA/ACTB expression levels are reduced in diabetic individuals compared to control (n=43; *p<0.05; $$p<0.01) and pre-diabetic (n=43; 
































































































Figure 3. 3. OGA expression levels decrease with increasing HbA1c levels (ADA 
criteria). 
n = 15 n = 12 n = 17  n = 14 n = 11 n = 18  
n = 15 n = 10 n = 16  





3.1.2 Decreased OGT expression accompanies the onset of diabetes 
3.1.2.1 OGT expression is able to distinguish between control and pre-diabetic individuals  
(FPG, ADA criteria) 
We next investigated OGT transcript levels between our study population characterized 
according to ADA FPG diagnostic criteria. Diabetic study participants exhibited significantly 
lower OGT expression levels when compared to control individuals, normalized to all three 
reference genes. OGT was attenuated in the diabetic group compared to the control group by: 
17.2 ± 2.3% (GUS), 23.3 ± 5.6% (ACTB); and 26 ± 5.1% (RPL37A), respectively (Figure 3.4 
A, B, C). In addition, OGT was differentially expressed between the control and pre-diabetic 
groups by 11.5 ± 5.4% (GUS) and 17.5 ± 5.5% (ACTB) (Figure 3.4 A, B). RPL37A 
normalized data exhibited a decrease in OGT expression in the diabetic group vs. the pre-
diabetic group (19.2 ± 5.6%) (Figure 3.4 C). 







A: Decreased OGT/GUS expression in diabetic (n=46; **p<0.01) and pre-diabetic (n=46; #p<0.05) groups compared to the control group. 
B: OGT/ACTB is decreased in the pre-diabetic (n=47; **p<0.01; $$$p<0.001) and diabetic (n=47; *p<0.05; ##p<0.01) groups compared to 
control individuals. C: OGT/RPL37A levels are attenuated with diabetes compared to controls (n=47; **p<0.01; ###p<0.001) and pre-
diabetics (n=47; $p<0.05). 
 
3.1.2.2 OGT expression levels are reduced in diabetic individuals (fasting blood glucose, 
WHO criteria) 
When classed according to FPG (WHO criteria), diabetic volunteers similarly displayed 
attenuated levels of OGT compared to control individuals for all three reference genes. 
Normalization to GUS; ACTB and RPL37A resulted in an 18.4 ± 1.8%; 23.2 ± 5.6%; and 24.4 
± 5.3% reduction in OGT, respectively (Figure 3.5 A, B, C). As with the ADA criteria, 































































































Figure 3. 4. A reduction in OGT is accompanied with both pre-diabetes and diabetes 
(FPG, ADA criteria). 
n = 21 n = 13 n = 12 
n = 23 n = 12 n = 12 
n = 20 n = 14 n = 13 





individuals, i.e. a reduction of 19.7 ± 6.3% (Figure 3.5 B). OGT normalized to RPL37A 
showed a decrease of 25 ± 5.3% in diabetic volunteers compared to pre-diabetic individuals 





A: OGT/GUS is decreased in diabetic individuals compared to controls (n=45; **p<0.01). B: OGT/ACTB levels are decreased in diabetics 
(n=44; **p<0.01) and pre-diabetics (n=44; *p<0.05) compared to control volunteers. C: OGT/RPL37A expression is attenuated in the 
diabetic group vs. the control (n=46; **p<0.01) and pre-diabetic (n=46; #p<0.05; $$p<0.01) groups. 
 
3.1.2.3 Decreasing OGT expression with rising HbA1c levels (ADA) 
When volunteers were characterized using HbA1c levels (ADA criteria), OGT expression 




























































































Figure 3. 5. OGT expression is diminished in diabetic individuals classed according to 
FPG levels (WHO criteria). 
n = 23 n = 11 n = 11 n = 23 n = 9 n = 12 
n = 23 n = 10 n = 13 





GUS showed a 23.6 ± 2.2% decrease, while OGT normalized to ACTB and RPL37A 
presented a 17.8 ± 4.5% and 23.3 ± 3.1% reduction, respectively (Figure 3.6 A, B, C). Also, 
normalization to ACTB allowed us to distinguish between control and pre-diabetic volunteers 
with a 21 ± 6.7% decrease (Figure 3.6 B). RPL37A enabled differentiation between diabetics 
and pre-diabetics, i.e. we found a 28.8 ± 3% (Figure 3.6 C).  
 
 
A: OGT/GUS expression decreases in diabetics vs. control (n=45; ***p<0.001) and pre-diabetic (n=45; ##p<0.01) individuals. B: 
OGT/ACTB is attenuated with diabetes (n=41; *p<0.05) and pre-diabetes (n=41; *p<0.05) compared to controls. C: OGT/RPL37A is 































































































Figure 3. 6. OGT expression is attenuated with increasing HbA1c levels (ADA criteria). 
n = 14 n = 13 n = 18 n = 14 n = 9 n = 18  
n = 14 n = 10 n = 16  





3.1.3 Investigation into GFPT expression levels 
3.1.3.1 GFPT1 levels remain unchanged with increasing fasting plasma glucose and HbA1c 
levels, respectively 
Due to the relatively low concentration of GFPT in our samples, we were compelled to run 
GFPT1 and GFPT2 at a higher cDNA concentration, leaving insufficient amounts of cDNA 
to normalize to all three reference genes. Hence GFPT1 and GFPT2 were only normalized to 
GUS and not to ACTB and RPL37A. 
 
GFPT1 expression levels revealed no statistically significant differences between any of the 
three study groups (control, pre-diabetic and diabetic) using all three classification criteria 
(FPG ADA and WHO, HbA1c ADA).  
 
A: GFPT1 remains unchanged with increasing fasting plasma glucose levels (n=40) (ADA criteria). B: GFPT1 displays no differential 
expression between study groups (n=42) (fasting plasma glucose WHO criteria). C: Increasing HbA1c levels do not affect GFPT1 





























































































Figure 3. 7. GFPT1 expression is unaltered with diabetes (all classification criteria). 
n = 20 n = 10 n = 10 n = 21 n = 10 n = 11  
n = 15 n = 9 n = 17  





3.1.3.2 GFAT2 expression is unchanged with increasing HbA1c levels (ADA criteria) 
Our initial investigations into GFPT2 expression levels yielded non-significant results 
between all three study groups, according to fasting plasma glucose levels (ADA and WHO 
















A: No statistically significant differences are observed in GFPT2 expression levels with increasing FPG levels (n=39) (ADA criteria). B: 
GFPT2 is not differentially expressed between study groups (FPG WHO criteria). C: GFPT2 regulation is unaffected by increasing HbA1c 


































































































Figure 3. 8. GFPT2 displays no significantly differential regulation between study 
groups (all classification criteria). 
n = 18 n = 12 n = 9  n = 22 n = 8 n = 11  
n = 16 n = 10 n = 21  





3.1.3.3 GFAT2 exhibits ethnic-dependent regulation 
Upon closer examination of individual GFPT2 relative expression ratios, we observed a very 
large inter-individual variability among these ratios (Figure 3.9). The variability appeared to 
be ethnic related; consequently we decided to separately examine GFPT2 expression levels 











Owing to the relatively small number of Mixed Ancestry participants we were unable to 
examine GFPT2 expression in this group only; however we were able to do so for the 
Caucasian population. Here, when participants were classified according to HbA1c levels, we 
observed a reduction of 54.7 ± 5.3% and 38.8 ± 12.2% in the diabetic and pre-diabetic vs. 
control groups, respectively (Figure 3.10 A). The same trend was observed when patients 
were characterized according to fasting blood glucose levels (ADA and WHO criteria); 
however these data were not significant (data not shown due to space constraints). Since 

















































Figure 3. 9. A graphic representation of the large inter-individual variability observed 
with GFPT2 expression 





account of large inter-individual variability (that was not seen with any of the other HBP 
regulatory genes examined in this study), we next investigated differential GFPT2 expression 
between Caucasian and Mixed Ancestry participants, regardless of diagnosis. After correcting 
for diabetic status, our data exposed a 2.4-fold increase in GFPT2 expression levels in the 
Mixed Ancestry group compared to the Caucasian group (Figure 3.10B).  
 
It must be noted here that no other ethnic-related differences were found in any of the genes 
examined in this study (see Figure 3.10 C for an example). 
 
 
A: GFPT2 is decreased in the Caucasian diabetic (n=34; **p<0.01) and pre-diabetic (n=34; #p<0.05) group vs. matched controls. B: Mixed 
Ancestry individuals display a 2.4-fold increase in GFPT2 levels compared to Caucasian individuals, despite diagnosis (n=36; **p<0.01). 




























































































Figure 3. 10. GFPT2 displays ethnic-dependent regulation whereas other HBP 
regulatory genes do not (HbA1c classification, ADA criteria). 
n = 14 n = 10 n = 10  n = 18 n = 18  
n = 18 n = 18  





Since GFAT is encoded by two separate genes; GFPT1 and GFPT2, we next investigated 
differences between our three study groups for GFPT1 and GFPT2 levels combined. Since 
GFPT2 exhibits ethnic-dependent regulation, we attempted to separately analyze the above in 
each ethnic group. However, once again the number of Mixed Ancestry participants was 
inadequate for such analyses. Nevertheless, Caucasian diabetic and pre-diabetic individuals 
displayed significantly lower expression of GFPT1 in combination with GFPT2 (more 
statistically significant than GFPT2 levels alone) when characterized according to HbA1c 
ADA criteria. Diabetic volunteers presented with a marked reduction of 36.3 ± 4.9%, and 
likewise pre-diabetic individuals by 43.6 ± 6.2% when compared to matched controls (Figure 
3.11).  When patients were characterized according to fasting plasma glucose levels (ADA 
and WHO criteria) similar trends were observed, although never reaching statistical 
significance (data not shown).  
 
 











































Figure 3. 11. Combined GFPT expression decreases in pre-diabetic and diabetic 
Caucasian individuals (HbA1c, ADA criteria). 
n = 16 n = 12 n = 8  





3.1.4 OGT expression may shed light on discrepancies that exist between FPG and 
HbA1c classifications 
Both the ADA and WHO define diabetes as a FPG of more than 7 mmol/l and an HbA1c 
level of >6.5%. After critical examination of our cohort, we found that 24.1% of individuals 
fell into this clear-cut category, while 53.7% of individuals displayed a FPG <7 mmol/l and 
HbA1c <6.5%. The other 22.2%, however, presented with a FPG <7 mmol/l, but an HbA1c 
of >6.5%.  
 
Since OGT was the most tightly regulated and most significantly differentially expressed 
HBP regulatory gene, we measured OGT/GUS transcript levels between these three groups: 
1) >7 mmol/l, >6.5%; 2) <7 mmol/l, <6.5%; and 3) <7 mmol/l, >6.5%. Significant 
differences were found between the >7 mmol/l, >6.5% and <7 mmol, <6.5%. Encouragingly, 
OGT expression was able to distinguish between individuals where FPG was both <7 mmol/l, 
but whose HbA1c was either >6.5% or <6.5% (Figure 3.12). Unfortunately, we were not able 
to assess OGT’s ability to distinguish between individuals presenting with a FPG of >7 
mmol/l in combination with either an HbA1c level of >6.5% or <6.5% as we did not have any 












(n=54; *p<0.05; **p<0.01; ###p<0.001). 
 
3.2 ASSESSING REGULATION OF THE PPP 
mRNA transcript levels were measured using qPCR and SYBR Green 1 chemistry was 
employed for the detection of gene transcript levels. Study participants were again 
characterized according to: 1) FPG, ADA criteria; 2) FPG, WHO criteria and 3) HbA1c 
levels, ADA criteria. Here we measured the expression levels of TKT and TKTL1; each 
normalized to GUS, ACTB and RPL37A. 
3.2.1 TKT expression essentially remains unchanged 
3.2.1.1 TKT expression is unaffected with increasing blood glucose levels (ADA and WHO) 
TKT mRNA levels, normalized to all three reference genes, indicated no statistically 
significant differences in the regulation between control, pre-diabetic and diabetic individuals 
(FPG, ADA and WHO criteria) (Figure 3.13 A - F). 






























Figure 3. 12. OGT expression differs between groups resulting from discrepancies 
between FPG and HbA1c diagnostic criteria. 
n = 29 n = 12 n = 13  







A: TKT/GUS remains constant with increasing plasma glucose levels (n=45) (ADA criteria). B: TKT/ACTB stays constant with rising 
plasma glucose levels (n=43) (ADA criteria). C: TKT/RPL37A is unchanged by increasing blood glucose concentrations (n=45) (ADA 
criteria). D: TKT/GUS is unaffected by diabetes diagnosis (n=43) (WHO criteria). E: TKT/ACTB expression is unaffected by rising blood 

























































































































































































E       F 
Figure 3. 13. TKT is not differentially regulated with increasing fasting blood glucose 
levels (ADA and WHO criteria). 
n = 23 n = 9 n = 11  n = 22 n = 9 n = 12 
n = 21 n = 11 n = 13  n = 23 n = 9 n = 11  
n = 20 n = 12 n = 13  n = 20 n = 12 n = 11  





3.2.1.2 TKT expression may be differentially expressed with increasing HbA1c levels (ADA) 
However, when participants were re-characterized according to HbA1c levels, TKT 
expression levels normalized to GUS and RPL37A were decreased by 22.9 ± 5.3% and 31 ± 
4.9%, respectively, between the diabetic group compared to the pre-diabetic group (Figure 





A: TKT/GUS expression level is decreased is diabetic individuals compared to controls (n=46; *p<0.05). B: TKT/ACTB remains constant 





























































































Figure 3. 14. HbA1c levels indicate a difference in TKT expression between diabetic and 
pre-diabetic individuals (ADA criteria). 
n = 14 n = 13 n = 19  n = 13 n = 8 n = 16  
n = 14 n = 9 n = 16  





3.2.2 TKTL1 is differentially expressed with diabetes 
3.2.2.1 TKTL1 levels are augmented with pre-diabetes and diabetes (FPG, ADA criteria) 
TKTL1 expression levels were markedly increased in diabetic individuals, characterized 
according to fasting blood glucose (ADA criteria), compared to healthy controls. TKTL1 
expression demonstrated an increase of: 98.6 ± 44.3%; 74.7 ± 37.2%; and 73.4 ± 43.7% in 
the diabetic vs. control group for all three reference genes: GUS; ACTB and RPL37A, 
respectively (Figure 3.15 A, B, C). In addition, TKTL1 expression levels were also elevated 
in pre-diabetic individuals compared to controls. Normalization to GUS revealed an 86 ± 
30.1% increase in TKTL1 in pre-diabetics; whereas normalization to RPL37A showed TKTL1 
levels to be increased by 73 ± 22.9% in the pre-diabetic group when compared to control 
individuals (Figure 3.15 A, C). 
 
 







A: Diabetic (n=38; *p<0.05; $$p<0.01) and pre-diabetic (n=38; #p<0.05) groups show elevated levels of TKTL1/GUS expression vs. 
controls. B: TKTL1/ACTB is increased in diabetic individuals compared to controls (n=40; *p<0.05). C: TKTL1/RPL37A is augmented in 
diabetic (n=37; *p<0.05) and pre-diabetic (n=37; *p<0.05) groups when compared to control individuals. 
 
3.2.2.2 WHO classification alters the observed significance of TKTL1 up regulation 
When volunteers were re-characterized according to the WHO criteria for FPG, specifying a 
pre-diabetic category of 6.1 - 6.9 mmol/l (vs. the ADA’s more conservative 5.6 - 6.9 mmol/l), 
the observed statistical significance was largely lost. Despite trends remaining similar, only 
normalization to GUS revealed a statistically significant increase in TKTL1 expression levels 
































































































Figure 3. 15. TKTL1 expression increases in parallel with higher fasting blood 
glucose levels (ADA criteria). 
n = 18 n = 10 n = 10  n = 19 n = 11 n = 10  
n = 17 n = 10 n = 10  







A: TKTL1/GUS levels are increased in diabetic volunteers compared to healthy counterparts (n=40; *p<0.05). B: TKTL1/ACTB is not 
differentially expressed with diabetes diagnosis (n=40). C: TKTL1/RPL37A is not significantly altered by increasing blood glucose levels 
(n=41). 
 
3.2.2.3 HbA1c characterization fails to significantly enhanced TKTL1 with diabetes 
Despite the increase of 58.1 ± 28%  in TKTL1 expression in the diabetic group vs. the control 
group and 84.5 ± 38.2% vs. the pre-diabetic group (normalized to ACTB) (Figure 3.17B); as 
with the WHO fasting plasma glucose criteria, TKTL1 upregulation with diabetes is no longer 
statistically significant when characterized according to HbA1c levels (ADA criteria) (Figure 



























































































Figure 3. 16. TKTL1 is largely unchanged with increasing FPG levels (WHO criteria). 
n = 22 n = 8 n = 10  n = 23 n = 7 n = 10  
n = 23 n = 7 n = 11  








A: TKTL1/GUS is not significantly altered between study groups (n=32). B: TKTL1/ACTB is upregulated in the diabetic group compared to 
control individuals (n=34; *p<0.05). C: TKTL1/RPL37A shows no significant differences between groups (n=37). 
 
The large SEM between study groups (indicated graphically by the use of error bars) 
indicates that TKTL1 relative expression ratios were grouped closely together for the control 
group (represented graphically by a smaller error bar); but as glucose dysregulation increased 
(with increasing fasting plasma glucose), TKTL1 expression levels became more widely 



























































































Figure 3. 17. HbA1c levels, for the most part, do not alter TKTL1 expression (ADA 
criteria). 
n = 12 n = 7 n = 13  
n = 14 n = 7 n = 13  
n = 13 n = 7 n = 17  
















3.3 REGULATION OF THE POLYOL PATHWAY WITH DIABETES 
3.3.1 The polyol pathway may be differentially regulated with the onset of pre-diabetes 
and diabetes 
3.3.1.1 AKR1B1 expression is unaffected by rising blood glucose levels (ADA) 
Examination of AKR1B1 transcript levels revealed no significant differences between our 






















































Figure 3. 18. TKTL1 inter-individual variability increases with rising blood glucose 
concentrations (ADA criteria). 








A: AKR1B1/GUS is not differentially expressed between study groups (n=45). B: AKR1B1/ACTB expression remains constant between 
groups (n=42). C: AKR1B1/RPL37A is not significantly different between controls, pre-diabetics and diabetics (n=44). 
 
3.3.1.2 AKR1B1 levels are attenuated with pre-diabetes (FPG, WHO and HbA1c, ADA) 
However, when study participants were re-characterized according to WHO criteria, GUS 
and ACTB normalized data showed a decrease in AKR1B1 expression levels with the onset of 
pre-diabetes. AKR1B1 was decreased by 21.5 ± 4.9% (GUS normalized) and by 30.9 ± 5.1% 
(ACTB normalized) in the pre-diabetic group versus control individuals (Figure 3.20 A, B). 
However, data normalized to RPL37A indicated no significant differences between the three 

































































































Figure 3. 19. Increasing blood glucose levels have no effect on AKR1B1 expression (ADA 
criteria). 
n = 21 n = 12 n = 12  n = 19 n = 12 n = 11  
n = 20 n = 12 n = 12  








A: AKR1B1/GUS is decreased in pre-diabetic individuals vs. controls (n=46; *p<0.05). B: AKR1B1/ACTB expression is reduced in the pre-
diabetic group when compared to the control group (n=42; **p<0.01). C: AKR1B1/RPL37A is not differentially expressed with diabetes 
(n=50). 
 
The same changes were observed when patients were characterized according to HbA1c 
levels (ADA criteria), although here we observed a slight decrease in AKR1B1 expression 
levels (18.1 ± 4.6%) in the diabetic group when compared to controls, for GUS normalized 
data (Figure 3.21 A).  ACTB normalized data showed a difference of 28.9 ± 6.8% between the 
control and pre-diabetic groups (Figure 3.21 B). Again, ARK1B1 normalized to RPL37A 



































































































Figure 3. 20. AKR1B1 levels are attenuated with the onset of pre-diabetes (FPG WHO 
criteria). 
n = 26 n = 8 n = 12  n = 25 n = 8 n = 11  
n = 27 n = 10 n = 13  








A: AKR1B1/GUS is decreased in the diabetic group when compared to controls (n=43; *p<0.05; ##p<0.01). B: AKR1B1/ACTB is reduced in 






































































































Figure 3. 21. Varying expression of AKR1B1 with increasing HbA1c levels (ADA 
criteria). 
n = 16 n = 9 n = 18  n = 15 n = 10 n = 19  
n = 16 n = 12 n = 19  
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Even with the current diagnostic tools at our disposal, diabetes remains largely under-
diagnosed (22). As discussed, there are several aspects that hinder the accurate and successful 
diagnosis of diabetes including: biological shortcomings of each assay (41); a lack of 
standardization in diagnosis due to alternative diagnostic approaches (41) and the incongruity 
between organization-specific cut-off criteria (28). Since diabetes and other non-
communicable diseases have reached epidemic proportions (7) and the consequences thereof 
are both detrimental to the individual and the economy (19), exploration into novel diagnostic 
tools for the earlier detection of diabetes is a reasonable initiative. Hyperglycemia-induced 
flux through alternative NOGPs is strongly linked to the development of insulin resistance 
and diabetes-associated pathologies (105). Consequently, we hypothesized that the genes 
encoding the regulatory enzymes of these respective pathways may be differentially 
expressed between control, pre-diabetic and diabetic individuals, so representing an 
exploratory and novel diagnostic avenue, based on genetic biomarkers, for the earlier 
recognition of type 2 diabetes.  
 
The conclusions drawn from this study are: 
1) OGA expression decreases in diabetic subjects 
2) Pre-diabetic and diabetic individuals present with decreased OGT expression levels 
3) GFPT2 expression exhibits ethnic-dependent regulation  
4) GFPT1 mRNA levels are not significantly altered with diabetes 
5) TKT expression does not vary significantly between study groups 
6) Pre-diabetic and diabetic subjects display increased levels of TKTL1 
7) AKR1B1 expression may potentially be decreased with the onset of pre-diabetes 
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4.1 OGA EXPRESSION DECREASES IN DIABETIC SUBJECTS 
OGA encodes the protein O-GlcNAcase which is responsible for the removal of O-GlcNAc 
moieties from target proteins (178). Although normalizing to three separate reference genes 
and different characterizations yielded varying degrees of sensitivity, the same fundamental 
trend was observed: decreased OGA expression in diabetic persons.  
 
Since increased O-GlcNAcylation of target proteins accompanies diabetes and OGA is 
responsible for the removal of O-GlcNAc moieties, our finding of decreased OGA expression 
levels in diabetic individuals was not surprising. All three classification groups (i.e. FPG, 
ADA criteria; FPG, WHO criteria and HbA1c, ADA criteria) demonstrated a decrease in 
OGA expression for the diabetic group compared to control individuals (Figure 3.1 A, B; 
Figure 3.2 A, B, C; Figure 3.3 A, B, C). Moreover, when patients were characterized 
according to WHO criteria pre-diabetic individuals also presented with attenuated OGA 
levels compared to controls, thus potentially allowing for the earlier detection of type 2 
diabetes (Figure 3.2 A, B). These data visibly illustrate how OGA sensitivity is affected when 
participants are differently characterized, thereby emphasizing the consequences of 
conflicting diagnostic thresholds. This is a trend that is observed throughout the Results 
section. 
 
The outcome of decreased OGA expression is consistent with earlier clinical studies 
presenting increased O-GlcNAcylation with type 2 diabetes (43) (159). Therefore, lower gene 
expression of the enzyme responsible for the removal of O-GlcNAc moieties in diabetic 
individuals may support the reported elevation in O-GlcNAcylation. Furthermore, laboratory 
studies have described the manifestation of insulin resistance/ type 2 diabetes with the use of 
O-GlcNAcase inhibitors (164).  Additional support for decreased OGA/ O-GlcNAcase 
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expression with diabetes comes from a study carried out on a Mexican American population. 
Here researchers found that a mutation in the OGA gene resulted in the early termination of 
OGA translation leading to decreased expression and increased susceptibility to type 2 
diabetes (67). The finding of decreased OGA corroborates previous work carried out in our 
laboratory where we found reduced leukocyte OGA protein expression in diabetic patients 
characterized according to HbA1c levels (189). Here patients characterized according to FPG 
levels (ADA and WHO criteria) displayed the same trend; however only apparent when 
employing additional selection criteria, i.e. diabetics with a fasting plasma glucose level of 
>9 mmol/l. This suggests that variations in expression at the gene level may be more 
sensitive than the protein level when examining OGA levels.  
 
Conversely, there have also been reports of increased OGA expression with human type 2 
diabetes, although on the protein level. For example, Park et al. (2010) reported augmented 
OGA protein expression in erythrocytes of diabetic individuals (43). Likewise, in the study 
previously carried out in our laboratory when OGA protein expression levels were measured 
in leukocyte sub-populations (i.e. granulocytes and lymphocytes), diabetic individuals now 
presented with augmented OGA levels (159). Both groups proposed that this may be an 
adaptive response in order to decrease high levels of O-GlcNAcylation, thereby restoring 
function to the cell and avoiding the damaging effects of hyper-O-GlcNAcylation. 
 
We propose that the incongruities observed between the studies discussed above and the 
present one may stem from a variety of sources. It is our opinion that the specific cell type 
under examination (erythrocytes vs. total leukocyte population vs. granulocytes and 
lymphocytes) may greatly impact on the observations since different cell types may contain 
varying numbers of O-GlcNAc modifiable proteins and exhibit distinct O-GlcNAc cycling 
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rates (159). In addition, differences in population admixture may affect observations. 
Moreover, it has been proposed that due to the highly complex regulation of both OGA and 
OGT, mRNA levels may not necessarily correlate with what is observed on the protein level 
(160). Regardless of such inconsistencies, our data reveal a timely and significant decrease in 
OGA expression levels which supports the notion of increased O-GlcNAcylation with type 2 
diabetes and provides impetus for further investigation. 
  
4.2 PRE-DIABETIC AND DIABETIC INDIVIDUALS PRESENT WITH 
DECREASED OGT EXPRESSION LEVELS 
O-GlcNAc transferase is encoded by the OGT gene and is ubiquitously expressed and highly 
conserved among species (170) (171). OGT is responsible for the dynamic addition of O-
GlcNAc moieties onto serine/ threonine residues of target proteins (146).  
 
Since previous studies reported increased O-GlcNAcylation with the progression of type 2 
diabetes (43) (159), we anticipated increased expression of the gene encoding the enzyme 
responsible for the addition of O-GlcNAc molecules to target proteins in diabetic individuals. 
Our data pointed to a statistically robust and early decrease in OGT expression levels (Figure 
3.4 A, B, C; Figure 3.5 A, B, C; Figure 3.6 A, B, C). When study recruits were classed 
according to FPG (ADA criteria), pre-diabetic and diabetic individuals exhibited reduced 
OGT expression compared to the control group (Figure 3.4 A, B). This finding, as with OGA, 
highlights the effects that organization-specific diagnostic thresholds may have on sensitivity. 
However, this result was surprising and raises the question how to reconcile attenuated OGT 
expression with higher O-GlcNAcylation typically found with type 2 diabetes. We suggest 
that this subtle, yet significant decrease in OGT expression at the pre-diabetic and diabetic 
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stage may represent an adaptive response in order to decrease the number of O-GlcNAcylated 
proteins under hyperglycemic conditions and consequently minimize the damaging effects 
associated with hyper-O-GlcNAcylation. Since it is well recognized that the O-GlcNAc 
modification rapidly responds to external stimuli such as an increase in nutrients in order to 
maintain protein stability, activity and function; it is reasonable to assume that cells would 
attempt to decrease O-GlcNAcylation in order to maintain proper cell functionality (146). Of 
note, diabetic patients displayed greater reductions in OGA expression relative to OGT 
suggesting that despite an attempt to lessen O-GlcNAcylation (by reducing OGT expression) 
and restore balance, the reduction in OGA expression outweighs the proposed adaptive 
response and could ultimately result in increased global O-GlcNAcylation, characteristic of 
diabetes.  
 
Conversely, others (including our research group) found unchanged levels of OGT in diabetic 
individuals, albeit on the protein level. However, our research group experienced difficulty in 
quantifying OGT levels due to limitations of the antibody employed and hence the data 
should be interpreted with caution (159) (189). The other study that examined OGT levels in 
erythrocytes (43) employed Western blotting as the primary method for OGT detection. This 
is a more qualitative method and certainly less quantitative than qPCR, the method used in 
this study. In addition to the variability that may stem from the use of different techniques, 
the complex regulation of OGT could also impact on the variability observed between the 
protein and gene level (160).  In addition to regulation by UDP-GlcNAc concentrations, OGT 
also readily undergoes PTM that is regulated by a wide variety of kinases and can itself be O-
GlcNAcylated (163). As a result, changes at the mRNA level may not directly correlate with 
protein expression/ enzyme activity. Moreover, OGT is alternatively spliced to produce three 
distinct isoforms localized to different tissues/ cellular compartments (168) and investigation 
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into isoform expression levels should also be analyzed when commenting on total OGT 
expression. All the complexities discussed above need to be deliberated when examining 
OGT fluctuations in response to hyperglycemia as OGT defies regulation by a single 
mechanism and consequently many factors may impact upon its expression level. 
 
Both the ADA and WHO define diabetes as a FPG of more than 7 mmol/l and an HbA1c 
level of >6.5% (26). After critical examination of our cohort, we found that a relatively large 
number of volunteers (22.2%) presented with a FPG <7 mmol/l, but an HbA1c of >6.5%, 
resulting in a conflict of diagnosis and further highlighting the discordances that exist 
between glucose based assays and HbA1c testing. A recent study also encountered this issue 
with up to 78% of their study cohort falling into this category (190). Such discrepancies have 
serious repercussions and can potentially lead to misdiagnosis if either the glucose-based 
assay or HbA1c assay are used in singularity. Unfortunately the use of a single diagnostic test 
is often a reality due to financial constraints (49). 
 
We consequently attempted to determine if OGT expression levels could differentiate these 
conflicting groups from one another. Further investigation into the diagnostic capability of 
OGT revealed that expression levels were able to distinguish between those individuals who 
presented with a FPG level of <7 mmol/l, but who exhibited either an HbA1c of >6.5% or 
<6.5% (Figure 3.12). Such findings further increase the potential of OGT expression levels in 
accurately diagnosing type 2 diabetes and reflect its ability to define changes in glycemia.  
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4.3 GFPT1 mRNA LEVELS ARE NOT SIGNIFICANTLY ALTERED WITH 
DIABETES 
Together, GFPT1 and GFPT2 encode for GFAT, the rate-limiting enzyme of the HBP (181) 
(182). GFPT1 expression was unaffected by increasing FPG (ADA and WHO criteria) and 
HbA1c levels (Figure 3.7 A, B, C), nor did it display ethnic-related differences at baseline 
(Figure 3.10 C). GFPT1 is primarily regulated on a post-transcriptional level (191) and so we 
were not surprized to not find any statistically significant differences in GFPT1 expression 
with increasing blood glucose concentrations or HbA1c levels. It is likely that GFPT1 may be 
post-transcriptionally and/ or post-translationally regulated and hence unaltered mRNA levels 
would not necessarily confer unchanged enzyme activity/ protein expression. In support, 
Robinson et al. (2007) measured GFPT1 mRNA levels and enzyme activity in diabetic rats 
and found that while enzyme activity was substantially down-regulated, GFPT1 mRNA 
levels remained constant, implying post-transcriptional regulation (192). Thus while GFPT1 
mRNA levels are not significantly altered between control, pre-diabetic and diabetic 
individuals the enzyme activity may be differentially regulated between these groups. We 
therefore recommend measuring enzyme activity and protein expression levels in parallel 
with mRNA levels when assessing overall GFAT expression in response to diabetes. 
 
4.4 GFPT2 EXPRESSION EXHIBITS ETHNIC-DEPENDENT REGULATION 
Initially we observed no significant changes in GFPT2 expression (Figure 3.8 A, B, C) 
according to FPG and HbA1c classifications. However, the large inter-individual variability 
we observed with GFPT2 expression levels (Figure 3.9) prompted us to separately examine 
expression levels for the two participating races. Due to the relatively small sample size we 
were unable to perform this analysis for the Mixed Ancestry group alone. However, 
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Caucasian pre-diabetic and diabetic individuals displayed a marked decrease in GFPT2 
expression levels compared to control individuals (HbA1c characterization) (Figure 3.10 A).  
 
Since GFAT regulates HBP flux (129) and increased O-GlcNAcylation is associated with 
type 2 diabetes (43) (159), we were surprized to find attenuated levels of GFPT2 in pre-
diabetic and diabetic individuals. Furthermore, our data are in disagreement with others who 
reported higher GFPT2 mRNA expression levels in diabetic individuals from the Indian 
subcontinent (184). Such inconsistencies may be due to the technique employed to measure 
GFPT2 expression, e.g. the Indian study used semi-quantitative PCR that is known to have 
several methodological limitations when compared to qPCR. In addition, these researchers 
examined GFPT2 levels in a leukocyte sub-population (lymphocytes) whereas we measured 
expression in the total leukocyte population. This once again highlights differences dependent 
on the cell type investigated and is a phenomenon we feel is very important when assessing 
HBP flux and regulation. Measuring HBP expression levels in the total leukocyte population 
as well as in leukocyte sub-populations may help to clarify this concept and allow for further 
comment. Since different cell types contain varying amounts of O-GlcNAc modifiable 
proteins with distinct cycling rates, it is rational to suppose that expression of HBP regulators 
may vary accordingly (159). GFPT2 mRNA down-regulation may also not necessarily 
correlate with enzyme activity and protein expression levels since GFPT2 undergoes post-
translational modifications (157) (193). However, since GFAT is negatively regulated by 
UDP-GlcNAc (151), and UDP-GlcNAc is the substrate for the O-GlcNAc modification 
(which is upregulated with diabetes), the observed decrease in GFPT2 expression in pre-
diabetic and diabetic individuals may be in response to increased levels of UDP-GlcNAc with 
hyperglycemia.  
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The concept of ethnic-dependent regulation is further supported by our finding that GFPT2 
expression levels demonstrated a 2.4-fold increase in the Mixed Ancestry population 
compared to Caucasian individuals, regardless of diagnosis (Figure 3.10 B). These data are 
consistent with another study where it was established that African-Americans exhibit a 2-
fold increase in GFPT2 expression compared to Caucasian individuals (194). Increased 
GFPT2 expression levels in the Mixed Ancestry population may also help explain the 
relatively high prevalence of type 2 diabetes in this population residing within the greater 
Cape Town region (Western Cape, South Africa) (195).   
 
Since both GFPT1 and GFPT2 encode the enzyme GFAT and the most statistical 
significance was observed with HbA1c characterization, we evaluated their combined 
expression level with increasing HbA1c levels.  
 
Here we found that the combined expression was significantly decreased in both Caucasian 
pre-diabetic and diabetic individuals, to a larger extent than GFPT2 alone (Figure 3.11). The 
enhanced statistical significance may be explained by the fact that GFPT1 is not primarily 
regulated at a transcriptional level and hence differences in GFPT1 expression (minor 
decrease in pre-diabetic and diabetic individuals, but not statistically significant) alone may 
not have reached statistical significance (Figure 3.7 C), but when combined with GFPT2 the 
collective statistical significance was enhanced (Figure 3.11). 
 
4.5 TKT EXPRESSION DOES NOT VARY SIGNIFICANTLY BETWEEN STUDY 
GROUPS 
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Transketolase is encoded by the TKT gene and is the rate-limiting enzyme of the non-
oxidative branch of the PPP (140) (142). A key function of the PPP is to produce the 
antioxidant NADPH that can be used to scavenge harmful ROS and hence this pathway is 
proposed to be beneficial during the onset and progression of diabetes (106), although this 
remains controversial (138) (139). This “protective” role is further acknowledged due to the 
ability of the PPP to shunt glycolytic intermediates into pentose reactions, thereby diverting 
flux through potentially damaging pathways (134). 
 
Our data reveal no statistically significant changes in TKT expression with increasing FPG 
levels using both ADA and WHO diagnostic criteria (Figure 3.13 A - F). These data are 
supported by current work in our laboratory that show no change in TKT protein expression 
levels with acute hyperglycemia (equivalent to pre-diabetes) in cell culture (Joseph DE and 
Essop MF, unpublished data). TKT mRNA expression levels alone may not be an accurate 
reflection of flux through the PPP, as a recent study found that diabetic individuals presented 
with a thiamine deficiency, an important co-factor for TKT, when compared to non-diabetic 
subjects (196). Hence flux through the PPP may additionally be affected by thiamine levels 
and this too should be considered when assessing PPP flux in response to hyperglycemia/ 
type 2 diabetes. Furthermore, two additional TKT-like enzymes (TKTL1 and TKTL2) (141) 
(142) that have proposed transketolase activity may form hetrodimers with TKT impacting on 
total transketolase activity and hence the flux through the PPP (197). 
 
When participants were characterized according to HbA1c levels, diabetic patients exhibited 
reduced TKT levels in comparison to pre-diabetic individuals (Figure 3.14 A, C). 
Characterization according to FPG levels revealed no statistically significant changes in TKT 
expression (Figure 3.13 A - F), while HbA1c levels did. Since diabetes is clinically defined 
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by increased blood concentrations (measured by FPG) and not by the extent of glycated 
proteins (measured by HbA1c levels), the two assays are proposed to identify different 
groups of diabetic individuals (40). Moreover, HbA1c measure the average glycemia over a 
three-month period compared to FPG that measures daily fluctuations in glycemia suggesting 
that HbA1c may provide a more stable, specific measurement of hyperglycemia (40). It is for 
these reasons that we may be observing a statistically significant difference in TKT 
expression levels when employing HbA1c diagnostic criteria compared to FPG criteria. 
 
This reduction may represent an “exhausted” PPP in diabetic individuals. Flux through the 
PPP may be increased in pre-diabetic individuals in an initial attempt to generate NADPH to 
aid in the scavenging of accumulating hyperglycemia-induced ROS. Eventually, the 
damaging effects of the alternative damaging pathways may outweigh the beneficial effects 
of the PPP, driving the body into a state of full-blown diabetes and further promoting flux 
through the harmful pathways with a consequential decrease through the PPP. These 
interesting concepts require further investigations to test whether this is indeed the case. 
 
4.6 PRE-DIABETIC AND DIABETIC SUBJECTS DISPLAY INCREASED LEVELS 
OF TKTL1 
In addition to TKT, there are two additional human transketolase-like proteins, TKTL1 and 
TKTL2 (142). TKTL1 is encoded by the TKTL1 gene that shares 61% sequence identity with 
TKT (198) and has recently received much attention in the literature due to the controversial 
debate regarding its proposed transketolase activity. Whereas some groups accept that 
TKTL1 possesses transketolase activity (141), Schneider et al. (2012) demonstrated the 
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converse with an elegantly designed deletion study (143). Therefore this issue remains 
unresolved and further studies are required to shed light on the precise function of TKTL1. 
While our findings do not in any way resolve this debate, they clearly (and to our knowledge 
for the first time) show that TKTL1 is differentially regulated with type 2 diabetes. Our data 
reveal that TKTL1 expression levels are significantly increased with rising blood glucose 
concentrations and can differentiate between control and pre-diabetic individuals as well as 
control and diabetic patients (ADA criteria) (Figure 3.15 A, B, C). However, when patients 
were characterized according to WHO criteria the observed significance was largely lost 
(Figure 3.16 A, B, C), demonstrating once again the impact of using different diagnostic 
thresholds. When employing the WHO’s reference range for pre-diabetes (FPG level of 6.1-
6.9 mmol/l), many ADA classified pre-diabetics now fall into the control group. Thus the 
sensitivity between control and pre-diabetic categories is lost with WHO characterization 
when compared to the more conservative characterization of the ADA (pre-diabetes: 5.6 - 6.9 
mmol/l). 
 
If TKTL1 truly does possess transketolase activity then we could assume that the PPP is up 
regulated with increasing FPG (ADA criteria). Since a previous study reported that targeted 
knockdown of TKTL1 caused a >50% reduction in total transketolase activity (199), this 
indicates that TKTL1 has a regulatory effect on total transketolase activity and thus it could 
mean that increased TKTL (with higher FPG) may reflect greater PPP flux, despite unchanged 
TKT levels. However, additional studies at the enzyme activity level are required to resolve 
this intriguing issue. 
 
It is well known that the PPP is responsible for the generation of NADPH, a key antioxidant. 
However, the PPP is also necessary for fatty acid metabolism (94) that is usually increased 
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with diabetes (12). Thus another possibility is that the upregulation of the PPP may occur 
with diabetes in order to support increased fatty acid metabolism. Higher PPP flux may also 
elicit additional metabolic effects. Since the PPP does not generate ROS (as the other 
damaging pathways do), the PPP may represent a safer, “ROS-free” way to metabolize 
surplus glucose in diabetic individuals (200). Together the upregulation of the PPP during 
hyperglycemia/ type 2 diabetes may support an increase in FFA metabolism (indicative of 
type 2 diabetes) and also possibly a “safer” alternative to metabolize surplus glucose. 
However, we propose that this protective capacity of the PPP is not sufficient to outweigh the 
harmful effects induced by the four damaging NOGPs and hence diabetes-associated 
complications will eventually arise (106). 
 
We found that TKTL1 inter-individual variability was lowest in the control group and higher 
in the pre-diabetic group while further increasing in the diabetic group (Figure 3.18). 
Whether this has implications is unknown as nothing was found in the literature to 
corroborate this finding, although it is interesting to note.  If TKTL1 does not in fact possess 
transketolase activity it may be safe to assume that whatever the function is, it is certainly 
linked to increased glucose metabolism. This is supported by the finding that TKTL1 mRNA 
expression is increased in many tumor cells when compared to healthy cells (201). 
Aggressive cancer cells often consume 20 - 30% more glucose than the average cell and 
accordingly, like type 2 diabetes, also represent a state of increased glucose metabolism 
(200). Moreover, increased TKTL1 expression seems to be generally harmful, e.g. others 
found negative correlations with increased TKTL1 expression (e.g. higher TKTL1 correlated 
with poor patient prognosis (202) and increased metastases (145)). To sum up we have 
shown, for the first time as far as we are aware, that TKTL1 is markedly increased in pre-
diabetic and diabetic individuals when compared to healthy controls (ADA criteria), 
Stellenbosch University  http://scholar.sun.ac.za




confirming a role in increased glucose metabolism. Thus TKTL1 gene expression analysis has 
potential as a novel diagnostic marker to help detect pre-diabetes and full-blown type 2 
diabetes. 
4.7 AKR1B1 EXPRESSION MAY POTENTIALLY BE DECREASED WITH THE 
ONSET OF PRE-DIABETES 
AKR1B1 codes for the enzyme aldose reductase that catalyzes the conversion of toxic 
aldehydes to inactive alcohols in the first step of the polyol pathway (116).  We found that 
AKR1B1 expression levels remained unchanged between control, pre-diabetic and diabetic 
volunteers with increasing FPG concentrations (ADA criteria) (Figure 3.19 A, B, C).  
 
AKR1B1 is predominantly expressed in tissues prone to diabetic complications (e.g. retinal 
cells) hence its strong association with diabetes-associated micovascular pathologies (116). 
For example, previous studies have found variants in the AKR1B1 gene to be linked with 
diabetes-related complications such as retinopathy, nephropathy and neuropathy (203). 
Several studies have also shown AKR1B1 gene and protein expression to be elevated in type 
2 diabetic patients suffering from microvascular complications (204) (205) (206).  
 
When participants were characterized according to WHO criteria pre-diabetic individuals had 
reduced levels of AKR1B1 when compared to control individuals. This finding remains 
unclear and a better patient history with consequent alternate classifications may help to 
clarify this finding. When study participants were characterized according to HbA1c levels, 
no consensus could be reached between the three respective reference genes and hence we are 
unable to comment on AKR1B1 expression in response to rising HbA1c levels (Figure 3.21 
A, B, C). To sum up, the likelihood of observing differential AKR1B1 gene expression is 
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much higher in diabetic individuals suffering from microvascular complications. Therefore 
we propose that it has poor diagnostic utility when employing leukocytes isolated from pre-
diabetic and full-blown diabetic persons. 
 
4.8 DIAGNOSTIC UTILITY OF GENE EXPRESSION IN TYPE 2 DIABETES 
Despite the identification of >40 type 2 diabetes risk loci, together they only account for  ~5 - 
10% of the well-established heritability observed with type 2 diabetes (54) . Accordingly, 
genetic variants may be less effective in tracking the progression of a disease where many of 
the commonly found “risk” genes only account for small effects. It has therefore been 
suggested that not only alterations in genomic sequences may confer disease susceptibility, 
but that altered gene expression may also play an important role (64). In light of this, it is our 
opinion that altered gene expression may prove useful to assist with the diagnosis of type 2 
diabetes.  
 
Our central hypothesis is that genes involved in the regulation of the HBP (such as OGA and 
OGT) would prove valuable since the endpoint of the pathway (O-GlcNAcylation) is 
upregulated with diabetes. The latter is widely implicated in the regulation of gene 
transcription, both directly through its association with RNA polymerase II (essential for 
catalyzing DNA transcription) and indirectly by modifying a host of transcription factors 
(extensively reviewed in (146)). O-GlcNAcylation is also nutrient-sensitive and therefore it 
acts as a significant link between environmental cues and the development of type 2 diabetes. 
In support, there is robust evidence that strongly suggests that O-GlcNAcylation plays a 
dynamic part in nutrient-responsive gene expression through its ability to regulate 
transcription (207). Dysregulated O-GlcNAcylation in response to hyperglycemia therefore 
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likely initiates changes in transcription (initially short-lived and reversible), but with 
prolonged and chronic hyperglycemia may become permanent and result in dysfunction 
(146). In light of these factors we are of the opinion that the HBP is a worthy candidate when 
exploring novel diagnostic avenues for type 2 diabetes. 
 
4.9 APPRAISAL OF THE METHOD EMPLOYED 
In order to determine differential gene expression in our cohort we employed the use of 
qPCR. We believe that qPCR is highly sensitive, quantifiable, reproducible, and time savvy 
and a high-throughput method that could be translated into a clinical setting, thereby lending 
diagnostic appeal (187). Moreover, there is room for improvement on the current study since 
enhanced detection chemistries that confer greater accuracy and specificity such as 
fluorescent probes (e.g. FAM versus SYBR Green I used in this study) could be employed 
(208). Fluorescent probes also allow for multiplex PCR, i.e. the assessment of more than one 
target gene in a single reaction well thereby enabling the assessment of a number of target 
genes in a limited time period (208). The sensitivity of detection may also be improved with 
the use of different reference genes. For the current study we employed three distinct 
reference genes that did not always yield the same statistical significance, but more reference 
genes should be evaluated in order to achieve the most accurate readings. Discrepancies such 
as these indicate that while the use of reference genes is the gold standard in qPCR (186), 
other methods such as linear regression of efficiency (LRE) (209) (less sensitive to inter-
individual variability) should be explored when attempting to normalize expression data as 
this could further enhance the potential of the current study. However, it is important to 
consider the cost of qPCR when proposing this method as an exploratory diagnostic avenue 
for diabetes. While it remains relatively costly, current diagnostic tests have all been 
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introduced, revised and amended over decades and consequently the same could be expected 
with the inception of a new diagnostic tool allowing time for the costs associated with qPCR 
to decrease (24). 
Despite the relative limitations of SYBR Green I technology (e.g. essential to use highly 
specific primer pairs as SYBR green binds to all double-stranded DNA) and the use of 
reference genes, we still managed to obtain statistically sound data and with the scope for 
methodological improvements we believe that differential gene expression has potential in 
the search for new diagnostic tools for the earlier and more efficient detection of type 2 
diabetes.  
 
4.10 LIMITATIONS OF THE STUDY 
Inevitable to research, this study was not without limitations and included the following:  
 
1) Although the use of reference genes is unavoidable and considered the gold standard 
in qPCR, our data clearly demonstrate that different reference genes yield varying 
degrees of sensitivity. The use of more than three reference genes would have been 
ideal to validate our results, but this was practically not possible due to time 
constraints, limited volumes of sample cDNA, and budgetary constraints. 
 
2) The ideal study cohort would have consisted of newly diagnosed patients who had not 
yet been exposed to glucose-lowering medications and exogenous insulin treatment as 
such treatment regimens may affect our results. However, due to the difficulty in 
obtaining type 2 diabetic volunteers such requests were unattainable.  
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3) A larger study population consisting of equal amounts of Caucasian and Mixed 
Ancestry individuals would have allowed us to determine the effects of ethnicity on 
gene expression. Although this was done in the Caucasian population, there were 
insufficient numbers of Mixed Ancestry volunteers from each group (control, pre-
diabetic and diabetic) to determine differential gene expression in this group alone. 
 
4) Gender, HIV status and prescribed medications were not taken into account when 
assessing differential gene expression. 
 
5) An important limitation to consider in this study is that the initial characterization of 
our study population is based on methods that are discordant and subject to their 
respective limitations, e.g. FPG is subject to large intra-individual variability.   
Thus it is possible that a number of volunteers may have been “incorrectly” 
characterized as only a once-off FPG reading was available for FPG ADA 
characterization. Moreover, although volunteers were reminded to arrive in a fasted 
state, some admitted to consuming beverages such as coffee or tea a few hours prior 
to assessment. Since the study guarantees patient anonymity we were unable to 
identify these patients retrospectively. The generation of false positives may also have 
resulted in mis-characterization that may ultimately skew our gene expression data by 
de-sensitizing differences between study groups. 
 
4.11 FUTURE RESEARCH RECOMMENDATIONS 
To further advance this study we would recommend the following: 
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1) In order to validate the current findings and further investigate differential gene 
expression as a potential diagnostic tool a much larger sample size is needed. This 
would also allow for the determination of the effects of gender and ethnicity on gene 
expression.  
 
2) To assess the effects of glucose-lowering medications and insulin treatment on gene 
expression. 
 
3) Investigate whether specimen collection in a non-fasted state would yield the same 
promising results as this is an appealing characteristic of a diagnostic tool.  
 
4) Include the measurement of enzyme activity and protein expression levels for the 
genes under investigation.  
 
5) To evaluate gene and protein expression, as well as the corresponding enzyme activity 
in different leukocyte subpopulations. Since more statistically robust protein data was 
previously obtained by our research group in granulocytes and lymphocytes versus 
total leukocytes, this may represent an opportunity to further strengthen the statistical 
significance observed in this study.  
 
6) While differential expression of HBP regulators shows great promise in diagnosing 
type 2 diabetes, an alternative route would be to examine the expression of OGT’s 
binding partners whose expression it is known to alter, particularly those involved in 
insulin signaling since it remains the key metabolic derangement in type 2 diabetes.   
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This preliminary study into the differential expression of key regulatory genes involved in 
alternative non-oxidative glucose metabolism shows reasonable potential. The early and 
significantly robust changes in HBP biomarkers is of particular interest due to its ability to 
detect the onset of both pre-diabetes and overt type 2 diabetes, and may offer diagnostic value 
in the future.  
 
This study also highlighted the need for investigation into such exploratory diagnostic 
avenues since current assays are discordant and discrepancies between organization-specific 
cut-off criteria greatly impact on the successful and accurate diagnosis of diabetes. Here our 
OGT data was able to discriminate between such discrepancies. Moreover, we believe that 
due to the tightly regulated, reversible, highly responsive, and metabolically integrating 
nature of the O-GlcNAc modification; gene expression in response to nutritional status (as 
regulated by O-GlcNAcylation) may represent a more stable, exceptionally sensitive 
measurement of average glucose fluctuations. We have also shown, for the first time, that 
TKTL1 is differentially expressed with pre-diabetes and overt type 2 diabetes and that despite 
its controversial function, it appears to play a role in increased glucose metabolism. This pilot 
study into the investigation of alternative NOGPs highlights the link between regulatory gene 
expression and altered glucose metabolism/ type 2 diabetes. The HBP and its biomarkers 
have clearly emerged as candidates that warrant further investigation into its potential use in 
the fight against the growing global diabetes epidemic. 
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